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Diabetes is a chronic metabolic disease that occurs when there is a 
deficiency in the production of insulin by the pancreas or when the body cannot 
effectively use the insulin it produces. Therefore, the treatment of diabetes aims to 
control the levels of glucose in the blood, which involves many different approaches, 
including insulin therapy many times.  
To date, even though many strategies have been proposed as alternative 
administration routes for insulin, subcutaneous injections still the most common 
administration route. To overcome the disadvantages imposed by the daily 
subcutaneous injections of insulin and to increase patient compliance, this thesis 
aimed to develop stable coated microneedles for rapid transdermal delivery of 
insulin. For that, polymeric microneedles made of a biocompatible resin class I were 
developed using 3D printing technology and studied along with a commercial 
metallic microneedle. The penetration studies showed that the 3D printed MNs 
presented superior penetration capacity compared to the metallic microneedles. 
To apply specific doses of insulin on the microneedles, an Inkjet printing 
technology was used. The SEM revealed the formation of fine layers on the 
microneedles without loss of insulin during the coating process. Moreover, Micro-
CT showed that the films stayed onto the MNs surfaces during the piercing.   
In order to address the challenges with insulin instability, different polymers 
and sugars were used as drug carriers to preserve insulin integrity during the coating 
process as well as to form uniform coating layers and facilitate rapid release rates. 
Circular dichroism and Raman spectroscopy demonstrated that most of the carriers 
maintained the secondary structure of insulin in its native form in the films. 
Moreover, X-ray diffraction analysis revealed that the insulin-carriers tended to 
originate amorphous films. The release studies using Franz cell diffusion showed 
that insulin is quickly released from the coated microneedles within 30 min. 
Furthermore, the animal studies showed that the coated 3D printed microneedles 
promoted a similar initial profile release to the SC injections, followed by a more 
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Diabetes mellitus is a chronic metabolic disorder characterised by high blood 
glucose levels that occurs when the insulin produced is not enough and/or when the 
body cannot use it effectively. When the diabetes is uncontrolled, the risk of 
infection, blindness, lower limbs gangrene and sometimes amputation thereof 
increase. In this direction, it is extremely important a safe and effective treatment for 
disease control, since there is no cure yet. The treatment involves a healthy diet, 
regular physical exercise, oral medications and in many cases daily injection of 
insulin (WHO, 1999, 2018). 
Like many drugs, insulin undergoes enzymatic degradation in the 
gastrointestinal tract and presents difficulties to permeate it. Although other routes 
of administration were proposed (Jose et al. 2012; Veuillez et al. 2001; Hollander 
2007; Yaturu 2013; Chaudhury and Das 2011; Viswanathan, Muralidaran and 
Ragavan 2017), the daily subcutaneous injection is the most common alternative. 
However, these hypodermic needles present some disadvantages such as local 
pain, allergy, lipodystrophy, hyperinsulinemia, fear of needles, anxiety and 
difficulties application for senile people (Kinesh et al. 2010; Ramaiya et al. 2018). 
Due to those issues caused by daily insulin subcutaneous injections of two 
or three times a day, several efforts have been made to improve insulin therapy and 
patient compliance (Khafagy et al. 2007; Brunton 2008). 
Transdermal administration is an excellent route for the administration of 
drugs that are degraded in the gastrointestinal tract. However, the barriers imposed 
by the skin, especially the stratum corneum and epidermis, limit the passage of 
substances through it. Thus, only lipophilic molecules and low molecular weight can 
cross these barriers and be absorbed into the bloodstream (Bariya et al. 2012). 
Though many different strategies have been studied to enhance skin 
permeability and create pathways big enough for molecules pass through it, the safe 
delivery of hydrophilic molecules and macromolecules still be a challenge (Benson 
2005; Paudel et al. 2010; Wu et al. 2019; Szunerits and Boukherroub 2018). 
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Recently, many studies have been reported great results using microneedles 
as an alternative transdermal delivery system to deliver a wide range of materials 
through the skin including insulin (Chen et al. 2016; Mahato 2017; Chen et al. 2015; 
Ross et al. 2015; Uddin et al. 2015). Microneedles are minimally invasive systems 
composed by micrometric needles included in the same array capable of creating 
superficial pathways across the skin to allow the drug bypass the stratum corneum 
layer of the epidermis and then be absorbed systemically without however 
stimulating nerves (Kim, Park and Prausnitz 2012). 
 Diabetes 
Diabetes is a worldwide chronical disease that according to its cause, it be 
classified by diabetes type 1 or diabetes type 2. Type 1 diabetes (formerly called 
insulin-dependent or childhood-onset) is characterised by irreversible destruction of 
pancreatic beta cells, which are responsible for the production of insulin. Because 
of the deficient insulin production, the body requires daily administration of insulin. 
On the other hand, type 2 diabetes (well known as non-insulin-dependent or adult-
onset) comprises 90% of people with diabetes around the world and usually is 
characterised by the body’s ineffective use of insulin. This type of diabetes is largely 
related to the excess of body weight and physical inactivity (WHO, 1999; 2013). 
The imbalance between insulin sensitivity and insulin secretion presented in 
type 2 diabetes leads to an increase of the insulin secretion in the early stage of the 
disease as a tentative to metabolise a given amount of glucose. However, the insulin 
production is slowly decreased with the progressive destruction of the β-cells 
(Niswender 2011). Unfortunately, as a result, it is estimated that about 50% of the 
patients with diabetes type 2 will require insulin therapy within 6 years follow-up 
(Wright et al. 2002).   
In both cases, hyperglycemia is a common effect of uncontrolled diabetes 
that over the time can lead to serious damage to many of the body’s systems, 
especially to the heart, blood vessels, eyes, kidneys, and nerves, affecting the 
patients’ quality of life (WHO, 1999; 2018). Then, optimal glycemic control in patients 
with diabetes can be achieved by a healthy diet, regular physical exercise, oral 
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medications and in many cases, daily injection of insulin which will altogether delay 
or even prevent those complications (American Diabetes Association 2010).  
Studies have shown that diabetes is one of the fastest growing diseases in 
recent years, affecting millions of people worldwide. According to the International 
Diabetes Federation (IDF) in its eighth edition of the IDF Diabetes Atlas (2017), it is 
estimated that 425 million of people are suffering from diabetes with ages ranging 
from 20 to 79 years. From those, 30.2 million are in the United States, 12.5 million 
in Brazil and 2.7 million in the UK. 
 Skin structure 
The skin represents 10% of the total body mass in adults, with an average 
total surface area of 2 m2 and it is one of the most important organs of the body 
responsible for several essential functions including the maintenance of the body 
hydration, thermoregulation, hormonal synthesis, sensory perception and barrier 
protection against exogenous substances (Barry 2007; Waugh, Anne; Grant 2014). 
The human skin is formed by three main layers which one with specific 
characteristics and some appendages such as hair follicles, sebaceous glands and 
sweat glands which offer aqueous channels into the skin (Figure 1.1). The exposed 
layer is the epidermis, followed by the dermis and finally the innermost layer, the 
hypodermis (HAE Benson, 2012). 
 




The epidermis is 150 –200 µm thick formed by a stratified squamous 
epithelium arranged in five distinct layers, the stratum corneum and four others 
viable layers: the stratum lucidum, stratum granulosum, stratum spinosum and 
stratum basale or germinativum at the bottom. Besides all these layers, the 
epidermis does not have a vascular network, so it obtains all its nutritional needs by 
passive diffusion through the interstitial fluid (Bruno, Miller and Lim 2013). 
Keratinocytes, Langerhans cells and melanocytes are the most common 
cells presents in the epidermis. The first ones are the main cells of the epidermis 
and reproduce themselves by mitosis at the stratum germinativum where they are 
attached to hemidesmosomes. The new cells produced slowly migrate towards the 
surface of the epidermis while their morphology gradually changes according to the 
maturation process through the layers. As they approach the surface, the cytoplasm 
is replaced by the fibrous protein keratin forming the stratum corneum (Alkilani, 
McCrudden and Donnelly 2015). 
Melanocytes synthesise the pigment melanin in the deep germinative layer 
which is absorbed by the surrounding epithelial cells (keratinocytes) and provides 
protection against UV radiation. The colour of the skin is related to the concentration 
of melanin present in the skin whereas the amount produced depends on the 
genetics factors of each person and the environmental stimulation. The more the 
skin is exposed to sunlight more melanin is produced to protect that skin (Waugh, 
Anne; Grant 2014). 
Finally, in a small proportion, Langerhans cells are antigens present in the 
stratum basale which can easily migrate to the epidermis or the dermis when it is 
needed and generate an immune response very easily (Benson 2012). 
Stratum corneum 
The stratum corneum is the main responsible for the efficient physical barrier 
of the skin. It consists of 10-30 layers (10-20µm) of maturated keratinocyte known 
as corneocytes which are mainly composed of keratin and lipid in a small proportion 
within a cornified cell envelope surrounded by a lipid extracellular matrix (Marwah 
et al. 2017). 
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Despite this efficient physical barrier, the skin has been explored for drug 
administration. The active molecules can be placed on the skin surface into an 
epidermal formulation such as cosmetics and insect repellents. They can also be 
delivered into deeper regions of the skin when it is in a topical formulation, or they 
can be absorbed systemically when designed for transdermal delivery which is an 
excellent route for administration of drugs that are degraded in the gastrointestinal 
tract (Bariya et al. 2012; Benson 2012).   
Dermis 
The dermis is a fibrous network of tissue that provides structure and 
resilience to the skin. It is approximately 3-5mm thick, consists of a matrix of 
connective tissue mainly composed of fibrous proteins such as collagen, elastin and 
reticulin which are surrounded by mucopolysaccharide  (Barry 2007). 
The dermis also contains many specialised cells and structures. The main 
cells present are fibroblasts, macrophages and mast cells whereas the main 
structures are sweat glands, sebaceous glands, hairs, sensory nerve endings and 
a rich capillary system (Waugh, Anne; Grant 2014). 
 Skin as a site of drug delivery  
Once in contact with the skin surface, molecules have three potential 
pathways across the epidermis: through sweat ducts, via appendageal route (hair 
follicles and sebaceous glands) or across the stratum corneum (Figure 1.2). For 
most compounds, the skin permeation is a combination of those pathways, although 
the predominant permeation route is across the continuous stratum corneum. 





Figure 1.2. Diagrammatic representation of the route of penetration of drug molecules via the stratum 
corneum (Benson, 2005). 
The stratum corneum permeation is due to passive absorption (diffusion) 
through the cells via transcellular route or into the cells via intercellular route  
(Benson 2012). 
In a transcellular diffusion, the molecules need to pass through the 
corneocytes and interleaving lipids. Therefore, the molecules need to be eighter 
hydrophilic due to the high amount of keratin inside of the corneocytes and 
hydrophobic due to the intercellular lipid matrix. Whereas the diffusion via 
intercellular route, the molecules need to show hydrophobic properties to diffuse 
and partition through the intercellular lipid matrix (Benson 2012). Then only lipophilic 
molecules and low molecular weight can cross these barriers and be absorbed into 
the bloodstream (Bariya et al. 2012). 
 Insulin 
 Insulin is an anabolic hormone secreted by the pancreatic β-cells that is 
responsible for the uptake of glucose, free fatty acids and amino acids into adipose 
tissue, muscle, and the liver. Therefore, this hormone influences the storage of all 
macronutrients, being essential for life (Niswender 2011). 
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Insulin is a small globular protein with 5800 Daltons and made up of two 
peptide chains A and B linked together by two disulfide bonds. The A chain has 21 
amino acids residues, it is fairly compact and consists of 2 sections of α-helix. The 
B-chain wrap around the A chain, and it has 30 amino acids residues and consists 
of a larger section of alpha-helix (Sluzky and Langer 1992; Ortiz et al. 2004). 
In the first 50 years after being discovered, insulin was extracted and purified 
from bovine and porcine pancreas. Only in the 1980s with the recombinant DNA 
techniques that human insulin became commercially available for therapy (Bethel 
and Feinglos 2005). The difference among the human, porcine and bovine insulin 
takes place in their first structure (in their backbone) (Figure 1.3). While porcine 
insulin differs by only one amino acid at B30 residue, bovine insulin differs by three 
amino acids at A8, A10 and B30 (Ortiz et al. 2004). 
 
Figure 1.3. Structure of human, bovine and porcine insulin molecules (Testa and Meyer 1996). 
Since the obtention of human insulin by recombinant DNA, many approaches 
have been studied to improve insulin therapy to approximate it to the physiological 
insulin profile (Melo et al. 2019). In healthy individuals, insulin is secreted in two 
phases 1) At a basal rate which is continuously released at low levels in response 
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to the endogenous glucose production from the liver and 2) In bolus, where insulin 
concentration quickly increases in response to food ingestion (Niswender 2011). 
Once the purpose of the treatment of diabetes with insulin is to regulate an 
adequate blood glucose level by mimicking the physiologic pattern of insulin 
secretion, many insulin analogs were proposed for both basal and bolus phases 
(Bethel and Feinglos 2005). Therefore, insulin preparations are available as short-
acting insulin to be used for bolus therapy (regular, lispro and aspart) and 
Intermediate (NPH) and Long-acting insulins (glargine and detemir) to replace the 
basal insulin secretion (Waller and Sampson 2018). 
 Insulin administration routes 
Once insulin is a protein that is degraded in the gastrointestinal tract, 
hypodermic needles, insulin infusion pumps, jet injectors and pens are the most 
common methods for daily administration. The problem lies on the main 
disadvantages such as local pain, allergy, lipodystrophy, hyperinsulinemia, fear of 
needles, anxiety and difficulties application for senile people (Kinesh, Neelam, Punit, 
Bhavesh, & Pragna, 2010). 
To overcome those issues, several non-invasive approaches for insulin 
delivery are being pursued. Nanoparticles, microparticles, micelles and other 
systems have been studied for oral administration of proteins (Jose et al. 2012; 
Chaudhury and Das 2011; Pan et al. 2002; Luo et al. 2016; Anselmo, Gokarn and 
Mitragotri 2018; Ibsen et al. 2018; Yaturu 2013). However, the low bioavailability still 
is the major challenge once insulin is degraded by the low pH in the stomach and 
by different digestive enzymes in the stomach and small intestine. 
The oral mucosa is also an alternative route for the administration of insulin. 
Although, only a few studies have evaluated the buccal route in humans (Veuillez 
et al. 2001; Senel et al. 2001; Heinemann and Jacques 2009). The main barrier here 
is the multi-layered structure of the oral epithelium combined with the continuous 
but highly variable flow of saliva which difficult the absorption of insulin. (Owens and 
Zinman 2003).  
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The pulmonary route for insulin delivery is an interesting route due to the 
large surface area and high permeability for drug absorption. The drugs can be 
formulated as dried powder or solutions and used like asthma inhalers. However, 
more studies need to be done to guarantee the safety of the lungs (Hollander 2007; 
Yaturu 2013; Sibum et al. 2018; Huang and Wang 2006). 
 Transdermal Delivery Systems 
Transdermal drug delivery systems (TDDS) are an attractive alternative route 
for drugs that undergo enzymatic degradation in the gastrointestinal tract or 
presents difficulties to permeate it, such as large and hydrophilic proteins. Those 
systems are designed to overcome the stratum corneum barrier and release the 
drug into the viable epidermis or dermis to be systemically absorbed without 
stimulating nerves or damaging the deeper tissues (Alexander et al. 2012). 
The key factors that determine the success of a TDDS are related to the 
physical-chemical characteristics of the drug into the formulation (partition 
coefficient, molecular size and solubility) the characteristics of the skin (if it is intact, 
skin age and site, degree of hydration and skin temperature) and finally, the area of 
application, if there is any pre-treatment of the skin and the contact time of the 
formulation with the skin (Alexander et al. 2012). 
In order to enhance skin permeability and create pathways big enough for 
molecules pass through it a number of different strategies ranging from chemical to 
physical methods have been studied (Benson 2005; Paudel et al. 2010; Chen et al. 
2009; Bolhassani 2019; Patel, Cholkar and Mitra 2014) and according to their 
approach and physical-chemical properties Prausnitz and Langer (2008) have 
classified the TDDS into 3 different generations: 
First generation TDDS 
The first generation of TDDS is represented by transdermal patches which 
are basically an adhesive to be placed on the skin where the drug can be stored into 
the adhesive layer or in a reservoir which is usually made by a special membrane 
to control the drug release through the skin. Along with those patches, metered 
liquid sprays, gels and other topical formulations were developed to be applied on 
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the skin. Furthermore, mostly small lipophilic and potent drugs can be delivered in 
the therapeutic range by passive diffusion alone through these systems. 
Even though the first-generation approach to transdermal delivery is limited 
primarily by the barrier posed by stratum corneum, many products used for clinical 
applications are in the market now such as patches of nitroglycerin, scopolamine, 
lidocaine, testosterone, estradiol, nicotine and many others (Al-Hanbali et al. 2019). 
Overall, the first-generation approach is used to deliver mostly small lipophilic 
and potent drugs once it is driven by passive diffusion alone. 
Second generation TDDS 
The second generation of TDDS includes conventional chemical enhancers, 
iontophoresis and non-cavitational ultrasound. Basically, all methods developed in 
this generation are guided by the necessity to increase skin permeability and 
application of an external driven force for transport the drug into the skin. 
Solvents and surfactants are the most common chemical enhancers used for 
transdermal delivery along with liposomes, dendrimers, microemulsions and 
prodrugs. Among the physical methods, iontophoresis is a technique used to 
enhance the transdermal delivery of charged compounds through the skin using a 
continuous low voltage current whereas non-cavitational ultrasound uses an 
oscillating pressure wave to disrupt stratum corneum lipid structure and thereby 
increase drug permeability. 
Third generation TDDS 
The third generation of TDDS aims a stronger disruption of the stratum 
corneum and employs techniques like chemical enhancers combined, biochemical 
enhancers, electroporation, microporation (thermal ablation, laser ablation and 
microneedles), cavitational ultrasound and microdermabrasion  (sandpaper and 
pressurized particles) (Prausnitz and Langer 2008; Paudel et al. 2010). 
Combinations of chemical enhancers 
Chemical enhancers are substances that facilitate transdermal drug delivery 
by altering the lipid structure of the stratum corneum and thus increasing its 
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permeability for molecules pass through it. Although there are several different 
categories of components, the delivery of high-molecular-weight compounds still a 
challenge and the irritation of the skin a major problem. To overcome those issues, 
different combinations of chemical enhancers at a low concentration and specific 
ratios can exhibit high potent penetration with a relative lack of irritation (Karande, 
Jain, & Mitragotri, 2004). 
Biochemical enhancers 
Biochemical enhancers are used to improve skin permeability using peptides 
which interact with the skin by different mechanisms increasing the amount of drug 
that can pass through the stratum corneum (Y. Chen et al., 2006; Kim, Ludovice, & 
Prausnitz, 2007; Li et al., 2008; Rothbard et al., 2000). A study shows that in some 
cases they can be much more effective when combined with a chemical enhancer 
(Kim et al., 2007). 
Cavitational ultrasound  
When applied to the skin, ultrasound can produce cavitation bubbles at low 
frequencies which can disrupt the stratum corneum structure and increase skin 
permeability. One knows that low-frequency ultrasound is capable of generating 
microbubbles in the water and tissue that after being collapsed generates water 
channels within the lipid bilayers (Baris E. Polat1, Douglas Hart2, Robert Langer1, 
2011; Smith, 2007). 
Electroporation  
In electroporation, high-voltage electrical pulses are applied in the skin for a 
few milliseconds to create transient disruptions in the structure of the stratum 
corneum which facilitate the transport of small and large molecules otherwise unable 
to permeate at all (Denet, Vanbever and Gale 2004; Ita 2016). 
Microdermabrasion 
Microdermabrasion uses pressurised particles, such as alumina or sodium 
chloride, to remove the stratum corneum and increases skin permeability. A similar 
effect can be achieved by using sandpaper. Though it was developed in the 1980s 
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for cosmetics procedures in order to reduce superficial scars, tattoos, wrinkles and 
fine lines, several studies have shown that microdermabrasion can be used 
effectively to increase transdermal delivery of low molecular weight compounds 
(Fujimoto, Shirakami and Tojo 2005; Andrews et al. 2011).  
Microporation 
Microporation involves the creation of microchannels in the skin in order to 
transport of water-soluble molecules and macromolecules through it. Thermal or 
radiofrequency ablation and laser ablation can create microchannels in the skin by 
exposure it to short, high-temperature pulses which can cause structural disruption 
and removal of stratum corneum without significantly heating or damaging the 
deeper tissues. Whereas microneedles create those channels by cutting a pathway 
in the skin (Banga, 2009). 
 Microneedles 
Microneedles are considered as a hybrid technique between hypodermic 
needles and transdermal patches and are composed of micrometric needles 
included in the same array (Figure 1.4), which depending on their size, they can 
pierce the stratum corneum and the epidermis without, however, stimulating nerves 
(Donnelly, Raj Singh and Woolfson 2010; Tuan-Mahmood et al. 2013). 
 
Figure 1.4. Comparison between hypodermic needle and microneedles (Martanto et al. 2004). 
Such systems are a promising strategy to deliver drugs independent of their 
size or lipophilicity and can be obtained from a variety of materials (metals, 
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polymers, silicon, ceramic) (Figure 1.5) and techniques (infrared laser, lithography, 
micromolds, electroplating, etching) (Mcallister et al., 2003, Tuan-Mahmood et al., 
2013; van der Maaden, Jiskoot, & Bouwstra, 2012).  
 
Figure 1.5. Solid microneedles made of silicon, metal and polymer (Kim, Park, and Prausnitz 2012). 
Usually, MN can be classified into 5 different types - poke-and-patch, coat-
and-poke, poke-and-release, poke-and-flow and hydrogel-forming MN as Figure 1.6 
shows. 
 
Figure 1.6. Schematic representation of Microneedles classification.I) poke-and-patch, II) coat-and-




In the poke and patch approach, solid microneedles arrays are used as a 
pre-treatment to pierce the skin and create microchannels upon which a transdermal 
patch or a conventional drug formulation is subsequently applied, and the molecules 
move passively through these microchannels. However, the major disadvantage of 
these solid microneedles is the requirement of a two-step application process (Tuan-
Mahmood et al., 2013). 
Coat-and-poke  
Coat and poke approach consists of solid microneedles coated with a 
drug/vaccine formulation that after being inserted into the skin the formulation is 
dissolved and the drug released. The major advantage is the avoidance of heating 
process (Vrdoljak et al. 2012; Harvinder S Gill and Prausnitz 2007). Such coated 
MNs have been used to deliver vaccines, proteins, peptides and DNA into the skin. 
(Larrañeta et al. 2016; Qiu et al. 2012). 
Poke-and-release 
Poke and Release are related to dissolvable microneedles which are made 
of soluble/biodegradable substances such as sugars, carbohydrates or synthetic 
polymers. Studies have been shown that those MN can be utilised to deliver a range 
of different substances including insulin (Ito et al. 2012; Liu et al. 2012; M.-H. Ling 
and Chen 2013)  and vaccines (Matsuo et al., 2012; Wu, 2013). They also have 
been used with iontophoresis (Garland et al. 2012). 
Poke-and-flow  
Poke and flow are related to hollow MN of different materials such as silicon, 
metal, hollow glass, polymers and ceramic. As the name suggests, there is a hollow 
inside of each microneedle through which the molecules can be transported to the 
interior of the epidermis. The microneedles have a conical geometry with an internal 
cavity which is also conical and through which a convective flux of drug is delivered 





Finally, hydrogel-forming MN arrays consist of MN made of polymers such 
as hyaluronic acid, agarose, chitosan, polyvinyl alcohol and many others 
compounds which exhibit the ability to swell in water and keep a significant amount 
of water within the structures. Attached to the baseplate of the array there is a patch 
containing the drug which rapidly diffuses through the swollen microprojections 
(Donnelly et al. 2012; Hong et al. 2014). They can also be made in a wide range of 
patch sizes and geometries and be easily sterilised. Furthermore, they can be 
employed to deliver high-molecular-weight compounds (Donnelly et al. 2012; 
Donnelly et al. 2014; Banga 2009; McCrudden, Alkilani, Courtenay, et al. 2014). 
 Even though many different MNs approaches have been developed, the best 
piercing properties are usually offered by solid MNs, mostly due to the inherent 
characteristics of the applied materials, yet, for most of them, the fabrication process 
is usually time-consuming and involve a complex multi-step process which can limit 
a scaling up production. In this sense, 3D printed microneedles can be an interesting 
strategy for the rapid fabrication of solid MNs with good mechanical properties.  
 3D Printed Microneedles 
3D printing is a family of different techniques that apply a computer model 
design to create physical three-dimensional objects. The main technologies that 
have or are expected to present the most promising contribution in the field of 
transdermal drug delivery, more specifically with microneedles are a) Fused 
Deposition Modelling and b) Photopolymerization-based technologies. 
 Fused Deposition Modelling (FDM) 
FDM is one of the most commonly 3D printing techniques and it is based on 
the melt-extrusion process where thermoplastic polymers in the form of filaments 
are heated and the semi-melted material is deposited in thin strands in a layer-by-
layer manner (Park et al. 2018). 
Although this technology has been demonstrating successful pharmaceutical 
applications in drug delivery (Goyanes, Chang, et al. 2015; Sadia et al. 2016; Alhijjaj, 
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Belton and Qi 2016), the resolution of elaborate structures in the microscale still a 
challenge and cannot be yet successfully applied for MNs fabrication (Economidou, 
Lamprou and Douroumis 2018; Low et al. 2017).  
 Photopolymerization-based technologies 
Photopolymerization-based technologies use photopolymer resin that is 
hardened or cured through a selective polymerisation upon laser stimulation. The 
most promising technologies in this group for microneedles applications are a) Two-
Photon Polymerisation (2PP), b) Stereolithography (SLA) and c) Digital Light 
Processing (DLP). 
Two-Photon polymerisation (2PP) 
The two-photon polymerisation (2PP) also uses photo-sensitive polymers 
with, however, a near-infrared laser with ultrashort pulses. In this case, the laser 
beam focus on local points volumes which is solidified by two-photon absorption. 
The main advantage of this technology is the capability of production of elaborate 
and complex structures in the micro and nanoscale (Gittard et al. 2010; Lee et al. 
2008; Zhou, Hou and Lin 2015). Although 2PP allows the manufacture of structures 
with small details, the technology still very expensive and the large industrial 
production of MNs could be a challenge. 
Stereolithography and Digital Light Processing  
SLA was the first commercially available solid freeform fabrication technique 
developed in the 1980s. This additive manufacturing process solidifies the liquid 
resin contained in a reservoir through an UV-laser beam process in a layer-by-layer 
manner while DLP is an evolution of SLA technology but instead of a laser beam, it 
uses a projector laser which makes it much faster than SLA once it prints the whole 




Figure 1.7. SLA and DLP photopolymerization laser mechanisms (Formlabs 2017). 
Although they follow the same principle, in the SLA technique, the laser beam 
solidifies the resin drawing rounded lines as it goes along, while in the DLP 
approach, a digital projector screen flashes a single image of each layer across the 
entire cross-section of the object. 
Even though DLP has the advantage of achieving faster print times, its 
resolution is dependent of the projector and it is limited by its fixed number of pixels, 
what makes it challenging to print small and detailed objects. In this sense, once 
SLA printers do not depend on the resolution of the projector, they are capable of 
printing small structure with a high resolution, making them a good option for 
transdermal delivery applications and microneedles fabrication. 
Among all the available materials for 3D printing, only a few biocompatible 
resins are available for stereolithography. Dental SG resin is an FDA approved 
Class I biocompatible resin (EN-ISO 10993-1:2009/AC:2010, USP Class VI) used 
for dental applications with excellent mechanical strength that can be successfully 
applied for fabrication of microneedles (Pere et al. 2018). 
Overall, 3D printing is a promising approach for MNs fabrication that 
overcomes many limitations and drawbacks imposed by other techniques such as 
costly equipment, multiple complex step-processes, time-consuming and difficult to 
scale up. 
 Coated Microneedles 
Many studies have been reported great results using microneedles to deliver 
a wide range of drugs (Martanto et al. 2004; Davis et al. 2005; Wu et al. 2010; Qin 
et al. 2012), however, the difficulty of dose control imposed by the two-step 
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administration process of solid MNs, the blocking channels with hollow MNs and the 
harsh processing conditions for manufacture dissolvable MNs are the most limiting 
factors for a successful therapy.  
On the other hand, coated microneedles is an appealing approach of 
transdermal delivery that involves only one-step administration process and can be 
used for rapid delivery of drugs (Kim et al. 2010; Ng, Fernando and Kendall 2012; 
Tas et al. 2012). It is made by solid microneedles coated with a drug formulation 
that after being inserted into the skin; the formulation is dissolved and the drug is 
released (Tuan-Mahmood et al. 2013). 
Among the great variety of coating methods already developed, the most 
popular used to coat microneedles are dip coating and spray coating. 
Dip coating 
In the dip coating method, the microneedles are coated by dipping the MN 
array into a drug solution and then allowed it to dry to form a solid film coating. Many 
studies with successful results have been reported using this technique (Harvinder 
S. Gill and Prausnitz 2007; Ameri et al. 2014). However, the major challenges 
related with this process are (1) the difficulty to obtain an uniform coating related 
with the surface tension and (2) the imprecision of the dose desired due the slow 
drying process during which the solution layer can move and be relocated off the 
MN surface and consequently reduce or vary the dose desired (Haj-Ahmad et al. 
2015). 
Spray coating 
Spray coating process is a reproducible and scalable process very common 
for coating tablets in the pharmaceutical industry that has been explored to film-coat 
microneedle arrays. Spray coating process undergoes three steps (1) atomisation, 
generation of fine droplets from the formulation, (2) the deposition and adherence 
of droplets onto the surface of MNs and the substrate and finally (3) the coalescence 
of droplets on the substrate forming an intact film coating (Vrdoljak et al. 2012; 
Perfetti et al. 2011; Haj-Ahmad et al. 2015).  The major issue related to this 
technique is the great loss of the coating material on the substrate as well as the 
difficulty to control a specific dose. 
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 Inkjet Printing 
Inkjet printing is a liquid deposition technique that can build two and three-
dimensional patterns and has been recently applied for coating solid MNs (Ross et 
al. 2015; Pere et al. 2018; Boehm et al. 2011; Uddin et al. 2015). Inkjet printing is a 
general term to describe both Continuous Inkjet (CIJ) and Drop on Demand (DoD) 
printings. Although they are guided for different physical process, they place tiny 
liquid drops which are digitally controlled (Daly et al. 2015). 
The inkjet printing used in this work is based on a drop on demand and it is 
basically formed by (1) a piezodriven dispenser, a pipette formed by a piezoelectric 
ceramic that is deformed upon voltage appliance, thus ejecting a droplet from the 
nozzle, (2) Oscilloscope which controls the operation process and (3) Stroboscope 
which catches images before and after samples dispensing, analysing the pipette 
performance (see Figure 1.8) (Uddin et al. 2015).  
a b c 
   
Figure 1.8. Inkjet coating of metallic microneedles array. (a) Drop diameter measured by a 
stroboscope. (b) MN positioned on a holder at an angle of 45°. (c) the overall image of the coating 
process (Modified from Uddin et al. 2015). 
The process involves the ejection of a fixed volume of the formulation  
(solution or dispersion of the drug) to a substrate which then dries through solvent 
evaporation. The drop volume range from picoliters to microliters depending on the 
nozzle dimensions (Boehm et al. 2013). 
 Microneedles for insulin delivery  
Recently, several polymeric and coated microneedles have been used to 
deliver a wide range of drugs into the skin in one step application process (Katsumi 
et al. 2012; McCrudden, Alkilani, Cian M McCrudden, et al. 2014; McGrath et al. 
2014; Lahiji, Dangol and Jung 2015)  but only a few studies involving insulin have 
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been done (Ito et al. 2006; Ito et al. 2012;  Liu et al. 2012; Ling and Chen 2013; 
Lahiji, Dangol, and Jung 2015). 
A study found that the amount of insulin loaded into the dissolvable 
microneedle can easily control the extent of the hypoglycaemic response. In this 
research, Liu et al. (2012) developed an insulin-loaded microneedles array using no 
heating step or organic solvents during its fabrication. They found that the 
microneedles made by hyaluronic acid using micromolding technique totally 
dissolved and released the insulin from microneedles within one hour.  
Another biodegradable microneedle patch made of 3-aminophenyl boronic 
acid-modified alginate and hyaluronate, made by micromolding technique, was 
developed for quick release of insulin in the interstitial fluid of skin. However, to 
reach the minimum blood glucose level, the MNs needed twice the time for the same 
dose of SC injection (2hs) (Yu, Jiang, Zhang, et al. 2017). 
Ling and Chen (2013) developed dissolvable MNs composed of starch and 
gelatin for rapid insulin release. In addition to the improvement of the insulin stability, 
the study showed that those polymeric microneedles can release the encapsulated 
insulin into the skin within 2 hours and exhibit an approximately 90% of the relative 
bioavailability  (M.-H. Ling and Chen 2013). 
In 2015, Lahiji et al. introduced a patchless dissolving microneedle called 
Microlancer. They proposed a carboxymethyl cellulose microneedle loaded with 
insulin whose needles are inserted into the skin through a device. They also 
compared the results of the insulin release profile and the in vivo delivery with the 
respective microneedles patch and the SC injection. They noted that the Microlancer 
insulin release was much more effective than its respective microneedle patch, 
reaching the minimum blood glucose level in 3 hours.  
Even though those studies have been shown considerable results, most of 
the polymeric materials used for dissolvable MNs are suitable for sustained delivery 
of drugs but not convenient for rapid transdermal delivery due to its slow-degrading 
properties (Liu et al. 2012; Xie, Li and Yu 2015).  
Moreover, the fabrication processes for the manufacture of dissolvable MNs 
is timing consuming and usually involves high temperatures and organic solvents 
which can limit the types of molecules that can be kept stable into the MN system. 
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Besides that, the incorporation of the drug inside the system can also compromise 
the mechanical strength of the MNs and therefore its performance. (Lee et al. 2015; 
Migalska et al. 2011). 
Since the inkjet printing was successfully applied to coat different active 
agents  onto MNs (Uddin et al. 2015; Boehm et al. 2013; Boehm et al. 2014; Boehm 
et al. 2011), in 2015, Ross et al. achieved uniform and reproducible polymeric-
insulin coatings on metallic microneedle arrays whose release studies revealed 
rapid insulin release profiles. 
To date, many interesting strategies have been proposed as alternatives to 
subcutaneous injection of insulin; however, only a limited number of studies has 
focused on the delivery of insulin through a transdermal route using microneedles. 
 Insulin stabilisers 
Among many materials that have been used for transdermal drug delivery, 
sugars and polymers are an interesting strategy to protect insulin molecules against 
degradation. Depending on their characteristics, they can also be used for rapid 
release of macromolecules such as insulin. In this sense, below are the selected 
materials used in this research. 
Gelatin 
Gelatin is a biopolymer obtained by controlled denaturation of collagen 
isolated from bovine and pigskin, cartilages and bones. Depending on the 
procedures of the pre-treatment of the collagen and the conditions of its 
denaturation, basically two types of gelatin can be obtained, type-A and type-B 
gelatin. Type-A gelatin is obtained under acid treatment conditions and has an 
isoelectric point at pH≈ 8-9 whereas Type-B gelatin is obtained under alkaline 
conditions and has an isoelectric point at pH ≈ 4-5 (Gomez-Guillen et al. 2011).  
Gelatins have been widely used in pharmaceutical applications as stabilisers 
of macromolecules due to its biodegradability, biocompatibility, non-immunogenicity 
and film-forming ability (Thyagarajapuram, Olsen and Middaugh 2007; Chen, Shyu 
and Chen 2018; Lee et al. 2017; Nair and Laurencin 2007). Furthermore, previous 
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studies have been shown that gelatin enhanced insulin absorption through 
transmucosal membranes (Seki et al. 2005). 
Soluplus 
Soluplus ® is a new polymer composed by 57% vinyl caprolactam, 30% vinyl 
acetate (hydrophobic groups) and 13% PEG 6000 (hydrophilic groups) whose 
molecular weight ranges from 90,000 to 140,000 Daltons. This polymer is soluble in 
water, acetone (up to 50%), methanol (up to 45%), ethanol (up to 25%) and 
dimethylformamide (up to 50%) (BASF 2010). 
Soluplus is a copolymer with amphiphilic properties that is widely used to 
stabilize molecules, enhance the solubility of poorly soluble drugs and promote fast 
drug release (Ross et al. 2015; Agrawal et al. 2016; Cavallari et al. 2016; Altamimi 
and Neau 2017; Homayouni et al. 2014; Paaver et al. 2014). 
Trehalose 
Trehalose is a water-soluble disaccharide with low chemical reactivity and a 
non-reducing nature. The anhydrous form (C12H22O11) has 342.31g/mol while the 
dehydrated form (C12H22O11.2H20) has 378.33 g/mol (Rowe et al. 2012b). Previous 
studies found that trehalose were capable of inhibiting or reduce aggregates of 
denaturated protein molecules (Singer and Lindquist 1998) and because its unique 
properties, trehalose has also been used to stabilize proteins and vaccines during 
dehydration processes (Haque et al. 2015; Chang et al. 2005; Allison et al. 1999; 
Yong et al. 2009; Faghihi et al. 2016). 
Recently, trehalose was also successfully applied for molecule stabilisation 
of dissolvable (Lee et al. 2011; Dillon et al. 2017) and coated microneedles (Ross 
et al. 2015; Pere et al. 2018; Tas et al. 2012; Kim et al. 2010; Choi et al. 2013). 
Those results are very promising and appealing for stabilisation of macromolecules 
for transdermal delivery through microneedles. 
Xylitol 
Xylitol is a natural sugar that occurs in many fruits. Industrially, it is commonly 
derived from various types of hemicellulose obtained from wood, corn cobs, cane 
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pulp, seed hulls and shells. This polyol (C5H12O5) has a molecular weight of 152.15 
g/mol and is highly soluble in water (Rowe et al. 2012c). 
Xylitol is largely used in the food industry and due to its extremely low relative 
glycemic response, it can also be safely consumed as a diabetic sweetener (Olinger 
and Pepper 2001). Besides that, xylitol is also widely used in the odontological and 
pharmaceutical industry (Dasgupta et al. 2017; Yu 2001; Ur-Rehman et al. 2013); 
Furthermore, previous studies showed that xylitol can be used to improve the 
stability of proteins and enzymes (Martin et al. 2012; Usha et al. 2006; Gekko and 
Mirikawa 1981) and also promote the rapid release of drugs (Pere et al. 2018; Arafa 
et al. 2016; Sjökvist and Nyström 1991). 
Mannitol 
Mannitol also occurs as a natural alcohol sugar (C6H14O6) that is largely used 
in the food, odontological and pharmaceutical industry (Olinger and Pepper 2001). 
Differently from its isomer sorbitol, mannitol is an inert non-hygroscopic powder 
(Rowe et al. 2012a). 
In the drug delivery field, several studies have been reported the good 
stabilisation properties of mannitol on proteins (Kim, Sioutas and Shing 2009), and 
enzymes (Izutsu, Ken-ichi; Yoshioka, Sumie; Terao 1994; Kim, Akers and Nail 
1998). Mannitol has also shown excellent properties to protect protein molecules 
during the dehydration process (Ohtake, Kita and Arakawa 2011) which makes it a 
good candidate for stabilising proteins of coated MNs.  
 Key objectives of the research 
The purpose of this research was to develop coated microneedles for rapid 
transdermal delivery of insulin by 1) Finding stable aqueous polymeric and sugary 
insulin formulations ratios for coating microneedles through inkjet printing, 2) 
Developing 3D printed microneedles using stereolithography technique, 3) 
Optimizing the coating formulations onto metallic and 3D printed MNs according to 
the required dose, 4) Evaluating the in vitro release of insulin by the MNs and 5) 
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HPLC INSULIN VALIDATION METHOD 
 Introduction 
High Performance Liquid Chromatography (HPLC) is a powerful analytical 
method used to separate, identify, and quantify compounds in a mixture. It consists 
of a stationary phase and a mobile phase. The sample is dissolved in the mobile 
phase and then forced through an immiscible stationary phase, the column. 
Two types of HPLC are used in pharmaceutical analysis, the normal one and 
the reverse one. In the normal HPLC, the stationary phase is made of highly polar 
compounds such as triethyleneglycol and the mobile phase is a relatively non-polar 
solvent such as hexane or iso-propylether. The reverse HPLC consists of a 
stationary phase made of non-polar hydrocarbons such as C18, C8, phenyl and the 
mobile phase which is relatively polar such as methanol, water, acetonitrile. 
The purpose of this study was to develop and validate a method using a 
simple, rapid, sensitive, precise, accurate and specific reversed-phase HPLC assay 
to quantify insulin from coating formulations for the in vitro studies. 
 Materials and Methods  
2.2.1 Materials 
Insulin solution from bovine pancreas (10 mg. mL-1), gelatin type A powder 
from porcine skin and trehalose dihydrate were ordered from Sigma-Aldrich. 
Soluplus ® was purchased from BASF. Xylitol (Xylisorb 90) and mannitol 
(Pearlitol) were donated by Roquette Freres (France). Saline Phosphate buffer 
PBS pH 7.4 was ordered from Sigma-Aldrich. Trifluoroacetic acid (TFA), acetonitrile, 




2.2.2 Chromatographic system and conditions 
The HPLC system used in the study consisted of an Agilent Technologies 
1200 series (Agilent Technologies, Cheshire, UK) equipped with a Phenomenex 
Jupiter 5 µ c18 300 Å, LC Column (250×4.60 mm, particle size 5 μm, Macclesfield, 
UK). 
Based on the literature review and in some previous tests, the mobile phase 
used for insulin analysis was water with 0.1% TFA and acetonitrile with 0.1% TFA 
(64:36 v/v). They were both degassed before running on the HPLC system. 
2.2.3 Validation of the method 
The validation of HPLC method for insulin was carried out following standard 
procedures described in the British Pharmacopeia and in the ICH Q2 (R1) (2005). 
The validation method included specificity, linearity, accuracy, precision 
(repeatability and reproducibility) limit of detection and limit of quantification. 
The analysis was performed in an isocratic elution mode and only after the 
column had reached the equilibrium (approximately 40-60 min at a flow rate of 1 
ml/min). The mobile phase was always filtered and degassed before use. The final 
flow rate was set to 1 mL/min, and the detector was set to monitor at 214 nm. All the 
analyses were carried out at 35 °C. 
2.2.4 Preparation of the stock solution  
Three insulin stock solutions were prepared in two different days by adding 
500 µL of insulin to a 50 mL volumetric flask and then diluted with PBS pH 7.4 up to 
the meniscus. The final concentration was 100 µg/mL, and the stock solutions and 
the buffer were made and used on the same day. 
2.2.5 Specificity  
For the specificity test, insulin was tested against all components present in 
the formulation using the same parameters. For that, all the components were 




The linearity of the developed method was accessed by the preparation of 5 
standard solutions in the concentration range of 10 to 50 µg/mL from each stock 
solution. All the samples were analysed in triplicate and the corresponding peak 
areas were determined and the calibration curves were plotted.  
2.2.7 Precision  
2.2.7.1 Repeatability (Intraday analysis) 
The repeatability of the method was carried out for insulin by analysing the 
sample at low (10 µg/mL), medium (30 µg/mL) and high (50 µg/mL) insulin 
concentrations, six times, in the same day. 
2.2.7.2 Reproducibility  
The reproducibility of the method was accessed by analysing nine samples 
of insulin at low (10 µg/mL), medium (30 µg/mL) and high (50 µg/mL) insulin 
concentration in two different days. 
2.2.8 Accuracy 
The accuracy of the method was analysed through the mean of the low (10 
µg/ml), medium (30 µg/mL) and high (50 µg/mL) insulin concentrations obtained by 
the previous tests and calculated by the following formula:  
 
Accuracy (%) = Concentration mean obtained experimentally 
                                    Theoretical concentration 
2.2.9 Detection limit and quantification limit 
The detection limit and the quantification limit were determined by diluting the 
insulin stock solution (100 µg/mL) from the initial concentration of 10 µg/mL and 
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gradually decreasing the concentration down to a point where the analyte could not 
be detected. The concentration of the insulin samples was 10, 5, 4, 3, 2 and 1 µg/ 
mL. Each concentration was analysed in triplicate and the detection limit (DL) and 
the quantification limit (QL) were calculated by the following equations: 
DL = 3.3 x SD 
         S 
 
QL = 10 x SD 
        S 
 
Where SD is the standard deviation of the y-intercepts of the regression lines. 
S is the slope of the calibration curve. 
 Results and discussion 
2.3.1 Selection of mobile phase 
Good peak symmetry for Insulin was achieved using the mobile phase 
consisting of water with 0.1% TFA and acetonitrile with 0.1% (64:36 v/v); isocratic 
mode. Insulin was analysed at 214 nm and its retention time was found to be about 
4.42 min. 
2.3.2 Specificity 
The specificity of the method analyses the ability of the method to measure 
the drug accurately and specifically in the presence of possible interferences such 
as the components of the formulation. Figure 2.1 shows the HPLC chromatograms 






















Figure 2.1.Chromatograms of pure insulin and insulin in the presence of different components in milli 
absorbance units (mAU). (a) pure insulin, (b) insulin:gelatin, (c) insulin:soluplus, (d) insulin:trehalose, 
(e) insulin:xylitol and (f) insulin:mannitol. The first two peaks are due to the solvents. The third peak 
is due to the insulin elution.  
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As the chromatograms show, the polymers used in the formulations do not 
interfere with the insulin peak at about 4.4 min. Then, the method can be used to 
quantify insulin in the proposed formulations. 
2.3.3 Linearity 
Linearity was evaluated through the regression line of the calibration curve in 
the range of 10 to 50 µg/mL. The linearity details of the insulin calibration curve and 
the parameters of its linear regression are illustrated in Figure 2.2 and Table 2.1. 
 
Figure 2.2. Calibration curve of insulin from 10 to 50 µg/mL. Insulin concentration (µg/mL) vs peak 
area in milli absorbance units (mAU), (n=9). 
 
Table 2.1.Parameters of the linear regression of the calibration curve. 
Parameters Values 
Linearity range (μg/mL) 10 to 50 
Angular coefficient 18.453 
Intercept -4.330 
Coefficient of determination 0.999 
 
The results showed a good coefficient of determination (R2 = 0.999) which is 




















achieved by this method in the range analysed and can be employed for the 
intended application of the method. 
2.3.4 Precision 
Precision is the level of agreement among individual results. While 
repeatability analyses the agreement among the individual results in a small period 
of time with the same instrument and analyst, the reproducibility analyses the 
agreement of the individual results in different days. 
The validation of the method was performed through examining the precision 
through repeatability and reproducibility. The theoretical insulin concentration, the 
mean peak areas and their respective standard deviations and the coefficient of 
variation (CV%) are presented in the Table 2.2 and Table 2.3.  
Table 2.2. Repeatability of the method for determination of insulin. 
 
 
Table 2.3. Reproducibility of the method for determination of insulin. 
 
The results obtained can be considered precise as the low CV (%) values 
obtained for insulin solution in saline phosphate buffer evidence an excellent 
precision. 
2.3.5 Accuracy 
Accuracy evaluates the closeness of the individual results are from the true 
value. Table 2.4 shows the determination of the accuracy of the method. 
Theoretical concentration (µg/mL)  Mean Peak Area DP CV (%)
10 173.863 5.521 3.176
30 547.969 2.404 0.439
50 923.165 4.807 0.521
Theoretical concentration (µg/mL)  Mean Peak Area DP CV (%)
10 178.965 8.706 4.864
30 546.359 14.105 2.582
50 917.852 24.282 2.646
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Table 2.4.Accuracy of the method for determination of insulin. 
 
According to the results, the method provides an accuracy of 99.35% on 
average, which means that the values measured are very close to the true value. 
2.3.6 Detection limit and Quantification limit 
The detection limit refers to the lowest amount of insulin that can be detected 
in a sample whereas the quantification limit is the lowest amount of insulin that can 
be quantitatively determined with suitable precision in a sample. 
The determination of the DL and the QL were based on 10, 5, 4 and 3 µg/mL 
by two approaches based on the standard deviation responses and visual 
evaluation (see Figure 2.3 and Table 2.5).  
 
 
Figure 2.3. Insulin chromatogram in milli absorbance units at 3 µg/mL. The first two peaks are due 
to the solvents. The third peak is due to the insulin elution. 
 
Table 2.5. DL and QL based on the standard deviation of the response and the slop. 
 
The minimum concentration able to be detected by this method was 3 µg/mL. 
Therefore, the DL and QL were determined at a range 10 to 3 µg/mL agrees with 









the results obtained once the detection limit is 2.107 but the quantification limit is 
6.385 µg/mL 
 Conclusion 
The validation of the HPLC method for quantification of insulin in the coating 
formulations was executed following the standard procedures described in the 
compendial methods of USP and ICH. The retention time obtained for insulin was 
about 4.42 min and the mobile phase used was water with 0.1% TFA and acetonitrile 
with 0.1% TFA (64:36 v/v). The selectivity tests showed that the method is able to 
detect insulin response in the presence of other components of the formulation. The 
calibration curve measuring the peak area against five insulin concentrations were 
found to be linear in the range investigated with a regression coefficient (R2) equal 
to 0.999. Considerable accuracy and precision were also acquired. Finally, the 
quantification limit (6.385 µg/mL) is far above the detection limit (2.107 µg/mL). 
Overall, the validation procedures showed that the developed HPLC method is 
reliable to identify and quantity insulin in the coating formulations. 
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METALLIC MICRONEEDLES FOR INSULIN DELIVERY 
 Introduction 
Transdermal drug delivery has revolutionised the pharmaceutical treatment 
of many diseases and improved the acceptance therapy of many people. In this 
sense, a wide range of drugs that are metabolised in the gastrointestinal tract can 
be now easily administered through transdermal patches (Al-Hanbali et al. 2019). 
However, the transdermal delivery of hydrophilic macromolecules using most of the 
proposed transdermal drug delivery systems (TDDS) is still a challenge and cannot 
be easily and quickly released into the systemic circulation due to the protective 
characteristics of the skin (Prausnitz and Langer 2008). 
To overcome the major limitations of the previous TDDS, transdermal 
microneedles (MNs) have been recently proposed as a new transdermal drug 
delivery strategy. Their prime advantages rely on the pathways created by the MNs 
across the skin which allows the easy passage of several different drugs, including 
high-molecular-weight molecules such as proteins and vaccines (Tuan-Mahmood 
et al. 2013; Liu et al. 2019; Choi et al. 2012; Tas et al. 2012; Sullivan et al. 2010; 
Kommareddy et al. 2013; Migalska et al. 2011). 
Among the variety of microneedles approaches already proposed in the 
literature (Larrañeta et al. 2016; Bariya et al. 2012), coated MNs present an 
interesting strategy for rapid release of drugs to the systemic circulation with the 
advantage of a single administration process (Ameri et al. 2014; Kellerman, Ameri 
and Tepper 2017; Pere et al. 2018; Cormier et al. 2004; Harvinder S Gill and 
Prausnitz 2007). The association of solid MNs made of stainless steel with inkjet 
printing coating technique is an interesting combination for a promising approach 
for insulin therapy once it allies the good mechanical properties of the metallic MNs 
with the accurate coating patterns of the inkjet printing.  
Since the inkjet technology was proposed to deposit active pharmaceutical 
molecules on different substrates in the last few years (Wu et al. 1996; Roth et al. 
2004; Yeo, Basaran and Park 2003; Sandler et al. 2011), many advances have been 
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made in the drug delivery field which also evolved with the application of inkjet 
printing for fast acquiring accurate and reproducible coatings on small devices 
(Tarcha et al. 2007; Li, Chen and Zhang 2018). Likewise, specific amounts of 
anticancer drugs (5-fluorouracil, curcumin and cisplatin) (Uddin et al. 2015), 
antifungal agents (miconazole, voriconazole) (Boehm et al. 2015; Boehm et al. 
2014), amphotericin B (Boehm et al. 2013) and insulin (Ross et al. 2015; Pere et al. 
2018) were successfully coated onto a wide range of MNs surfaces using inkjet 
printing. 
In this sense, polymeric solutions containing insulin at different ratios were 
proposed as coating formulations for protecting insulin against degradation as well 
as to promote a rapid release of the drug. Furthermore, the inkjet printing technique 
was used to overcome the usual drawbacks presented by the most common coating 
techniques. 
 Material and methods 
3.2.1 Materials 
Insulin solution from bovine pancreas (10 mg.mL-1) and gelatin Type A 
powder from porcine skin were purchased from Sigma-Aldrich. Soluplus powder, a 
co-polymer of polyvinyl caprolactame-polyvinyl acetate-polyethylene glycol was 
ordered from BASF. Phosphate buffer PBS 7.4 (Sigma-Aldrich) and all the solvents 
used were analytical grades. The metallic microneedles arrays were made 
according to previous work (Uddin et al. 2015; Ross et al. 2015) and donated by 
Prausnitz (Microneedle Systems, LLC). 
3.2.2 Penetration studies through porcine skin 
For the penetration studies, the metallic microneedles were inserted into the 
porcine skin samples using a texture analyser (Stable micro system) (n=6). The 
porcine skin samples were placed in waxed petri dishes at the bottom of the 
equipment and the MN arrays were mounted on the moving probe using double-
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sided adhesive tape. The continuous force and displacement measurements were 
recorded as the probe moved downward at 0.01 mm/s. 
3.2.3 Coating formulations 
Gelatin and soluplus were weighed, added to the insulin solution and then 
left it stirring until complete dissolution. The composition of the coating formulations 
used is shown in Table 3.1.  
Table 3.1. Composition of coating formulations 
Formulations Composition (w/w) 
Ins:Sol 2:1 10mg Insulin, 5mg Soluplus 
Ins:Sol 1:1 10mg Insulin, 10 mg Soluplus 
Ins: Gel 2:1 10mg Insulin, 5 mg Soluplus 
Ins:Gel 1:1 10mg Insulin, 10 mg Soluplus 
3.2.4 Coating of microneedles through inkjet printing 
The MNs were coated using an Inkjet printing Nanoploter II (Gesim, 
Germany). The arrays were positioned at 45° relative to the dispenser and the 
formulations were jetted through a piezodriven dispenser (pipette) (PicPip 300) onto 
the MN surface in the form of fine droplets of approximately 300 pl. For each coating 
cycle, 5 dots of two droplets of coating formulation were dispensed longitudinally to 
the axis of each MN. The process was repeated for 130 jetting cycles to coat the 
desired amounts of 4 IU/array (140µg). The microneedles were left at room 
temperature for 24hs for drying.  
3.2.5 Scanning electron microscopy (SEM) 
The metallic microneedle arrays were mounted onto a double-sided carbon 
adhesive tape on top of an aluminium stub. A Hitachi SU 8030 (Japan) was used to 
analyse each array by SEM using low accelerating voltage (2.0 kV). The images 
were digitally taken with different magnifications (30 and 50x). 
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3.2.6 Quantitative analysis of the amount of insulin coated on the MNs 
The metallic microneedles were coated with 4 IU (140 µg/mL) of insulin with 
insulin:soluplus and insulin:gelatin at 1:1 ratio (w/w) and left to evaporate at room 
temperature for 24hs. After dried, the coated MNs arrays were individually placed in 
a glass flask and 4 mL of PBS pH 7.4 was added to the MNs loaded with 4 IU. The 
vials were placed to sonicate for 5min, filtrated and the amount of insulin analysed 
by HPLC. The concentration of insulin was calculated using the analytical curve 
under the same conditions, and the percentage of the coating efficiency (CE%) was 
then calculated with the following equation:  
 
CE (%) = (The amount of insulin analytically determined) x 100  
                            Theoretical amount of insulin  
3.2.7 Circular Dichroism (CD) 
Insulin, gelatin and insulin-polymer solutions were diluted to 1.0 mg.mL-1 in 
saline phosphate buffer pH 7.4 (PBS) whereas their respective films were weighed 
and solubilized in PBS 7.4 also to 1.0 mg mL-1 of insulin concentration. The far-UV 
CD spectra were recorded between 190 and 260 nm on a Chirascan CD 
spectroscopy (Applied Photophysics, UK) using polarisation certified quartz cells 
(Hellma). The measurements were carried out at 20 °C using a step size of 1 nm, a 
bandwidth of 1 nm and an acquisition time of 1 sec. Four scans were recorded for 
each sample, averaged and the corresponding spectrum of water and polymer 
concentration, when required, were then subtracted from each spectrum. For 
estimation of the secondary structure composition of insulin, the CD spectra were 
evaluated by the CDSSTR method (Sreerama, Venyaminov and Woody 1999; 
Sreerama and Woody 2000) using Dichroweb website  (Whitmore and Wallace 





3.2.8 Raman spectroscopy 
Insulin and insulin-polymer films were analysed using Raman microscopy 
(Jobin Yvon LabRam I) with a laser of 532 nm wavelength coupled with an optical 
microscope with 50x objective. An average of 5 spectra and an acquisition time of 
5 seconds were used. 
3.2.9 X-Ray Diffraction (XRD) 
The X-ray diffraction patterns of the films of the raw materials and the films 
of insulin-polymer formulations were obtained using a Bruker D8 Advance 
(Germany) with a Göebel mirror using Cu-Kα radiation and operating at 40 kV and 
40 mA. The diffractograms were collected in two-theta (2θ) mode from 5° to 40° with 
a step size of 0.02° (2θ) and a counting time of 0.2 seconds per step. 
3.2.10 Stability of Insulin Films  
Circular dichroism and x-ray diffraction were used to study the stability of the 
insulin in the films at time zero (T0) and after 30 days (T30) kept in the fridge at 4 ± 
1oC using the same parameters as previously described. 
3.2.11 Preparation of porcine skin for in vitro release of insulin 
A full thickness of abdominal porcine skin was collected from a local 
slaughterhouse (Forge Farm Ltd, Kent, UK) and stored at 4°C until it was used. The 
skin was fixed on a polystyrene block previously wiped with 70% ethanol and both 
the fatty tissue below the abdominal skin area and the abdominal hair were 
removed. The skin was then treated with dermatome (Padgett dermatome, Integra 
LifeTMSciences Corporation USA) at an angle of ±45° and tissue samples with 1.0 
± 0.1mm thick were then placed onto filter paper soaked in a small amount of saline 





3.2.12 In vitro permeation of insulin through porcine skin 
The permeation studies were undertaken using Franz diffusion cells 
(PermeGear, Inc., PA, USA) and abdominal porcine skin. The cells were calibrated 
with phosphate buffered saline (PBS; pH7.4) at 6-6.5 mL per hour rate using an 
autosampler (FC 204 fraction collector, Gilson, USA) while the temperature was 
maintained at 37oC using an automated water bath (Thermo Fisher Scientific, 
Newington, USA).  
The metallic microneedles coated with 4IU of insulin:soluplus at 1:1 ratio 
(w/w) (n = 6) were inserted into the abdominal porcine skin for 30 s using manual 
finger pressure and placed on the donor compartment of the Franz diffusion cells 
with a total diffusion area of 1.1 cm2. Sample fractions were then collected every 10 
minutes, up to 1 h and the amount of insulin was analysed by the validated HPLC 
method described in chapter 2.  
At the end of the experiment, the MNs and the skin were individually placed 
in a glass flask with 1mL of PBS 7.4 and left it to sonicate for 5 min. After that, they 
were filtrated and analysed by HPLC in order to determine any remaining insulin on 
the MNs or in the skin.  Statistical analysis for the drug release was performed by 
using t-test (SPSS software Inc.), and a 0.05 significance level was adopted.  
 Results and Discussion 
3.3.1 Penetration of the metallic MNs in the porcine skin 
To access the required force for the metallic microneedles to pierce the skin, 
a penetration study using porcine skin was conducted. In this study, all the 





Figure 3.1. Force vs displacement curve for metallic microneedles penetration in the porcine skin. 
Maximum forces in Newton (N) for the penetration of the metallic microneedles: 3.86 N ± 0.41 (n=6). 
Although the fabrication and the physical characteristics of these metallic 
microneedles are described elsewhere (Ross et al. 2015), from this study, it is 
possible to see that these metallic microneedles, containing 50 needles per array 
required 3.86 N to pierce the skin. 
3.3.2 Scanning electron microscopy (SEM) of the coated MNs 
The SEM pictures (Table 3.2) shows that the inkjet printing deposited uniform 
layers on the surface of the microneedles and reveal that the method can be applied 
for coating microneedles with high precision and reproducibility without loss of the 
material on the substrate. 
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3.3.3 Quantitative analysis of the amount of insulin coated on the MNs 
The amount of insulin coated on the MNs (4IU) was quantified by HPLC and 
the analytical concentration was calculated using the calibration curve. The coating 
efficiency is showed in Table 3.2. 
Table 3.2. Coating efficiency of insulin-polymer formulations using inkjet printing method. 
 
From the results, it is possible to see that coated method applied for coating 
the metallic microneedles was very reliable and very close to the desired 
concentration which allows the delivery of precise doses. 
3.3.4 Characterisation of insulin-polymer formulations 
3.3.4.1 Circular Dichroism 
Circular dichroism (CD) is a spectroscopy technique that measures the 
difference in absorbance between left- and right-handed circularly polarised light of 
a chiral sample and generates a signal in terms of ellipticity (θ) in degrees. The 
secondary structure of proteins can be studied when its peptide bond region is 
analysed in the far UV CD spectra (Kelly, Jess and Price 2005; Martin and Schilstra 
2008). 
Once CD gives information about the secondary structure of a molecule, it 
can be used to study protein denaturation (Kelly, Jess and Price 2005; Greenfield 
2007). In this sense, CD spectroscopy was used to investigate the effect of different 
polymers on the insulin structure as well as its stability. The results were also used 
to estimate the insulin secondary structure content by CDSSTR method (Sreerama 
and Woody 2000; Whitmore and Wallace 2008). 
Figure 3.3 shows the CD spectra of pure insulin and gelatin at 1.0mg/ mL in 








Insulin:soluplus 140.00 139.93± 1.39 101.42 ± 1.54
Insulin:gelatin 140.00 141.99 ± 2.16 99.95 ± 0.99
57 
 
around 210 and 222 nm which is related to the α-helix and β-sheet structures as 
already reported by others (Yong et al. 2009; Andrade et al. 2015; Ettinger, 
Timasheff and Strycharz 1971). Gelatin, presents a negative peak at 198 nm related 
to its random coil form which agrees well with the literature (Sakai et al. 2018; Gopal 
et al. 2012; Liu et al. 2017). As previously studied, in aqueous solution, at a low 
concentration, gelatin chains tend to form intermolecular hydrogen bonds and adopt 
a coil conformation (Djabourov et al. 1988). As expected, soluplus did not show any 
CD signal. 
 
Figure 3.3. CD spectra of insulin solution and gelatin solution at 1.0 mg/mL in PBS 7.4. 
 
Figure 3.4 shows the CD spectra of insulin and insulin-polymer solutions at 
different ratios (w/w) diluted to 1.0 mg/mL in PBS 7.4. All insulin-polymer solutions 
showed minima peaks around 210 and 220 nm which are associated with α-helix 
and β-sheet structures. A reduction in the Molar ellipticity along with changes in the 
shape of the spectra was noticed for all samples, especially for insulin-gelatin 
formulations, indicating changes in the secondary structure of insulin. The 




















Figure 3.4. CD spectra of insulin solution and insulin-polymer solutions at different ratios (w/w) and 
1.0 mg/mL in PBS 7.4. 
 
Table 3.3. Percentage of the secondary structure content of insulin in insulin solution and insulin-
polymer solutions at different ratios (w/w). 
 
In order to evaluate the secondary structure content of insulin after 
dehydration, the respective films of insulin solution and insulin-polymer formulations 
were solubilised in PBS 7.4 and analysed by CD. Figure 3.5 shows the CD spectra 
of insulin solution in comparison with the corresponding films of insulin solution and 
insulin-polymer formulations at 1.0 mg/mL.  
From the spectra and the estimation of the secondary structure of insulin 
(Table 3.4), it is possible to see that even greater changes occur in the secondary 
structure of insulin for all samples upon dehydration. For insulin film, a noted 
decrease in the α-helix content along with an increase in the β-sheet and turn 
structures during dehydration were noted and it is in agreement with previous 





























2:1 1:1 2:1 1:1
Helix 50 43 47 36 32
β-Sheet 10 15 17 20 27
Turn 11 15 17 23 19
Random coil 29 26 18 20 22
Insulin (%)




Figure 3.5. CD spectra of insulin solution, insulin film and insulin-polymer films at different ratios 
(w/w) at 1.0mg/mL in PBS 7.4. 
 
Table 3.4. Percentage of the secondary structure content of insulin in insulin solution, insulin film and 
insulin-polymer films at different ratios (w/w).  
 
Many studies have shown that dehydration can lead to significant 
conformational changes in proteins resulting in partially or completely unfolding and 
loss of their biological activity even after rehydration (Prestrelski et al. 1993; Pierre 
O Souillac, Middaugh and Rytting 2002; Zeng et al. 2011). During drying, the 
removal of the water from the vicinity of the protein often perturbs its structure and 
force them to rearrange in order to compensate the lost hydrogen-bonds which is 
also affected by the dynamic and interactions among the molecules in the system 
(Ohtake, Kita and Arakawa 2011). 
In this sense, once insulin presents a tendency to lose its native secondary 
structure upon dehydration, many studies have been done with different additives 
and strategies in order to stabilise and protect insulin molecule from denaturation 





























2:1 1:1 2:1 1:1
Helix 50 46 41 45 32 21
β-Sheet 10 15 18 17 24 34
Turn 11 16 21 17 22 20
Random coil 29 24 20 21 21 25






All insulin-soluplus samples showed a slight shift to 208 nm and a decrease 
in the Molar ellipticity intensity, compared to the insulin solution sample. From the 
results, it is possible to see that a higher amount of soluplus prevented bigger 
changes in the secondary structure of insulin for both solution and film samples 
(Figure 3.3 and Figure 3.5). Furthermore, insulin:soluplus 1:1 ratio (w/w) film 
presented almost the same insulin structure content as the pure insulin film at time 
zero.  
Both insulin-gelatin ratios presented expressive changes in the secondary 
structure of insulin (Figure 3.4) with a further decrease in the Molar ellipticity upon 
dehydration (Figure 3.5). Moreover, the estimation of the insulin secondary structure 
content (Table 3.3 and Table 3.4) indicate a clear reduction in the α-helix content 
followed by an increase in the β-sheet and turn structures for all samples. 
Additionally, it was also noted that the higher the gelatin concentration, the 
bigger the reduction of the Molar ellipticity, indicating a decrease of the native insulin 
molecules in the system. These results might be due to intermolecular interactions 
and aggregation between insulin and gelatin and agrees well with other reported 
results regarding the reduction of the native conformation of proteins in the presence 
of gelatin (Gopal et al. 2012). 
Overall, although many studies have shown that hydrophilic polymers can 
interact and protect proteins through many specific and non-specific mechanisms, 
they can also enhance self-association and aggregation (Kamerzell et al. 2011; 
Ohtake, Kita and Arakawa 2011). Moreover, even though it is suggested that gelatin 
interacts with proteins in a specific protein-manner with electrostatic interactions 
playing an important role, the mechanisms by which gelatin interacts with proteins 
still not completely understood yet (Young et al. 2005; Thyagarajapuram, Olsen and 
Middaugh 2007; Olsen et al. 2003; Wang 2005). 
3.3.4.2 Raman Spectroscopy 
In the Raman spectroscopy, the scattered light is used to interrogate the 
nature of the sample within an irradiated volume. Basically, the energy from the 
excitation light can be absorbed, transmitted or scattered, which can be further 
classified as elastic or inelastic according to its properties. The elastic scattered light 
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or Rayleigh is the majority of the scattered photons whereas the inelastic scattered 
light, known as Raman scattering, is a rare event that occurs due to its interaction 
with the molecules in an irradiated sample (Smith et al. 2015). 
The pattern of Raman scattering can give important information about the 
identity of the molecules according to how those molecules interact with the electric 
field of the laser. Furthermore, the more easily the compound can be polarised the 
more intense the Raman signal will be (Goh, Ismail and Ng 2017). 
Amide I and III are important features in the Raman spectra regarding the 
secondary structures of proteins. According to Liu at al. (1972), the denaturation of 
insulin can be clearly investigated through the observation of the amide I peak in the 
Raman spectra between 1600 and 1700 cm-1. Liu and his colleagues demonstrated 
that the native insulin shows a broad peak band at around 1662 cm-1 and a shoulder 
near 1685 cm-1 assigning the α-helix structure and the random coil form. However, 
denaturated insulin has its amide I peak sharpened and shifted to lower frequencies 
(1673 cm-1) and no shoulder regarding the random coil form can be seen. 
In this research, the spectra of pure insulin (Figure 3.6) shows the amide I 
band at 1661 cm-1 and a shoulder near 1682 cm-1 related to the α-helix and the 
random coil form respectively, indicating the native form of insulin in the film. Peaks 
at 1242 cm-1 and 1273 cm-1 regarding amide III in the native insulin conformation 
can also be seen in the spectra and are related to random coil and α-helix structures, 
respectively. 
 
Figure 3.6. Raman spectrum of pure insulin film. 
 













Figure 3.7 shows the Raman spectra for all insulin-polymer films at different 
ratios (w/w). All films showed amide I peak around 1662 cm-1 and a shoulder near 
1685 cm-1 which correspond to the α-helix and random coil form assignments. 
Insulin-gelatin films did not show any distinctive peaks of gelatin whereas insulin-
soluplus films show the distinctive peaks of soluplus at 699, 1087 and 1738 cm-1. 
For both insulin-soluplus films, amide III bands slightly shift to higher 
frequencies around 1237 and 1271cm-1 whereas insulin-gelatin samples showed 
amide III peaks about the same frequency as the pure insulin film with however less 
resolved peaks. Similar behaviour was reported by Zeng et al. (2011) during insulin 
dehydration. They noted that amide III peaks become gradually unresolved and 
amide I band becomes wider as the relative humidity is reduced and the water is 
removed.  
 
Figure 3.7. Raman spectra of insulin and insulin polymer-formulations films at 2:1 and 1:1 ratios 
(w/w). 
Insulin has three disulphide bonds, one between A6 and A11 and other two 
that connect A and B chains, A7-B7 and A20-B19. These bonds are formed during 
the folding process and there are very important for stabilising the folded structure 
of insulin. The S-S bonds are also very sensitive to conformational changes in the 
molecule and their vibrations appear in the range of 500 - 550 cm-1 (Tensmeyer, 
Shields and Lilly 1990; Ortiz et al. 2004).  From the spectra, all insulin and insulin-
polymer films show similar Raman bands at about 509 cm-1 suggesting that the 
disulphide bonds of insulin adopt the most stable conformation in the dehydrated 
state, protecting its hydrophobic surfaces inside of its three-dimensional structure.  

















Among all insulin residues, Tyrosine (Tyr) is one of the most sensitive 
residues to the environmental changes. The doublet band located approximately at 
830 cm-1 and 850 cm-1 and its relative intensity of I850/I830  is sensitive to the hydrogen 
bonding of the phenolic hydroxyl group of the Tyr residues and can be used as an 
indicator of the state of the Tyr residues (Tensmeyer, Shields and Lilly 1990; 
Siamwiza et al. 1975; Zeng et al. 2011). From our study (Table 3.5), it is possible to 
see that all insulin-polymers showed an increase in the I850/I830 when compared with 
insulin film alone indicating that more Tyr residues are exposed, and more hydrogen 
bonds are formed when the polymer is present. 
Table 3.5. Relative intensity of Tyr residues of insulin and insulin-polymer films at different ratios 
(w/w). 
 
Another interesting Raman bands that involve Tyr residues are the peaks at 
1174 cm-1 and 1206 cm-1 and its relative intensity ratio I1174/I1206. Zeng et al. (2011) 
have demonstrated that its intensity ratio decreases as the water is removed from 
insulin crystals. It is interesting to note that insulin alone shows a significant water 
loss while more molecules of water were retained in the films containing the 
polymers.  
Overall, all the films showed an increase in the hydrogen bonding of insulin 
as well as an increase in their content of water in the dehydrated state. Although the 
circular dichroism studies point to a decrease in the native state of insulin, no 
specific signs of insulin degradation can be seen in the Raman spectra. 
3.3.4.3 X-ray diffraction (XRD) 
Insulin, the isolated polymers and insulin-polymer films were studied by X-
ray diffraction. Figure 3.8 shows the diffractogram of insulin which is predominantly 
amorphous with a small peak at 31.79°. Soluplus showed characteristics peaks at 
9.97°, 20.44°, 24,56° and 29.54° whereas Gelatin showed no crystalline peaks, 
indicating its amorphous nature. 
Insulin Film Ins:Sol 2:1 Ins:Sol 1:1 Ins:Gel 2:1 Ins:Gel 1:1
I852/I830 0.91 0.97 1.01 0.99 0.97
I1174/I1206 0.77 0.82 0.81 0.93 0.89
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Figure 3.8. Diffractograms of the films of the components of the formulations: (a) insulin, (b) soluplus 
and (c) gelatin. 
 
Figure 3.9 shows the diffractograms of insulin-polymer films. Insulin:soluplus 
(Figure 3.9, a) at 2:1 ratio showed crystalline peaks at 26.56° and 28.39° whereas 
the 1:1 ratio presented more crystalline regions with peaks at 18.22°, 20.16°, 26.56°. 
28.31° and 31.68°. It is interesting to note that the insulin characteristic peak only 



































































Figure 3.9. Diffractograms of insulin-polymer films at different ratios (w/w). 
Insulin-gelatin films (Figure 3.9, b) show a predominant amorphous state with 
some regions of crystallinity. The 2:1 ratio film showed peaks 6.82° 9.33° and 28.54° 
while the 1:1 insulin: gelatin showed more crystalline regions with peaks at 7.10°, 
12.35°, 26.54° and 28.40°.  
From the spectra, it is possible to see that the random coil form of gelatin is 
maintained after the dehydration of the pure gelatin solution, however, when gelatin 
and insulin are combined, gelatin presents a tendency to form a triple helix structure 
after dehydration, which is indicated by the formation of the characteristic peak near 
7°. It was also noted that the increase of gelatin concentration in the film leads to an 














































content. Furthermore, a shift of the triple helix peak towards greater 2θ values also 
may indicate the presence of stronger interactions between gelatin and insulin 
molecules, especially by electrostatic interaction. Besides that, the 31.79° peak of 
insulin completely disappears in the presence of gelatin. These results also agree 
with Raman and circular dichroism findings, indicating a strong interaction between 
insulin and gelatin molecules. 
3.3.5 Insulin stability  
Circular dichroism and x-ray diffraction were used to study the stability of 
insulin and insulin-polymer films during the time. The samples were analysed using 
the same parameters as before at time zero (T0) and after thirty days (T30) kept in 
the fridge at 4 ± 1°C. 
 Figure 3.10 shows the CD spectra of insulin film at T0 and T30 at 1.0 mg/mL 
in PBS 7.4. The spectra of insulin show a double minimum around 210 and 222 nm 
which are related with α-helix and β-sheet structures as already reported by others 
(Correia et al. 2012; Zhang et al. 2010). The main difference between the two insulin 
spectra is due to the decrease of the Molar ellipticity for the T30 samples which 
suggest changes in the secondary structure of insulin with reduction of the α-helix 
structure. The estimation of the secondary structure content of insulin (Table 3.6) 
indicates a decrease in the α-helix content while new β-sheet structures were 
formed. 
 






























Insulin T0 Insulin T30
67 
 
Table 3.6. Percentage of the secondary structure content of insulin of insulin films and insulin-
polymer films at different ratios (w/w). 
 
Figure 3.11 and Table 3.6 compares the CD spectra of the insulin-polymer 





Figure 3.11. CD spectra of insulin film and insulin-polymer films at different ratios (w/w) at time zero 
(T0) and after 30 days stored in the fridge at 4°C (T30) at 1.0mg/mL in PBS 7.4. 
From the results, it is possible to see that the secondary structure content of 
insulin slightly changed during the time for both insulin:soluplus ratios (w/w). 
Insulin:soluplus 2:1 ratio presented an increase in the α-helix structure along with a 
decrease in β-sheet content whereas insulin:soluplus 1:1 ratio maintained the same 
amount of α-helix content accompanied with the formation of more β-sheet and turn 
structures. 
As previously discussed, greater changes occur in the secondary structure 
content of insulin for insulin-gelatin formulations.  From Figure 3.11 (b, c) and Table 
3.6, it is possible to see that insulin:gelatin 2:1 presented almost the same α-helix 
content during the time with however an increase in the β-sheet structures. As it 
T0 T30 2:1 1:1 2:1 1:1 2:1 1:1 2:1 1:1 
Helix 46 44 41 45 44 45 32 21 33 19
β-sheet 15 19 18 17 16 19 24 34 26 36
Turn 16 14 21 17 21 18 22 20 23 23
Random coil 24 23 20 21 19 18 21 25 19 22







































































































shows, insulin:gelatin 1:1 also showed changes during the time, with a decrease in 
the α-helix content and an even greater increase in the β-sheet and turn structures. 
As mentioned earlier, the X-ray diffraction was also used to study the stability 
of the samples during the time. 
Overall, insulin presents a predominant amorphous nature with some regions 
of crystallinity which increase during the time. Figure 3.12 shows the diffractogram 
of insulin films at T0 and T30 kept in the fridge at 4 ± 1°C. At T0 insulin shows a 
small peak at 31.79° which has increased and shifted to 31.66° after 30 days in the 
fridge. Furthermore, a small peak at 28.33° was also present at T30 indicating the 
formation of new crystalline regions. These changes in the insulin diffractogram 
during the time may be due to expected changes in the freshly prepared amorphous 
system as already reported by others (Abdul-fattah et al. 2007). 
 
 
Figure 3.12. Diffractograms of insulin films at time zero (T0) and after 30 days (T30). 
Insulin:soluplus films showed a predominance of amorphous phase for both 
ratios at both times (Figure 3.13 a, b). At time zero, the 2:1 ratio showed small peaks 
at 26.42° and 28.27° which were slightly shifted to 26.56° and 28.39° after 30 days. 
Moreover, the intensity of the peak at ~28° increases and a new peak is formed at 
18.61°. The 1:1 ratio at time zero showed small peaks at 18.22° and 20.16° and 
higher peaks at 26.56°, 28.31° and 31.68° while the films after 30 days showed only 
the bigger peaks which were shifted to 26.32°, 28.39° and 31.69° respectively. The 






















31° is also reduced during the time which may be due to the changes in the lattice 










Figure 3.13. Diffractograms of insulin-polymer films at different ratios (w/w) at T0 and T30. 
 
It is possible to see from the diffractogram of insulin:gelatin 2:1 (Figure 3.13, 
c) that the peak at 6.82°and 28.54° at T0 has shifted to 7.21° and 28.27°, 
respectively during the time, while the peak at 9.33° disappears and new ones are 
formed at  22.98°, 29.28°, 36.01° and 39.45°. The absence of the insulin peak and 
the shift of the gelatin triple helix peak (~7°) suggest stronger interaction between 
insulin and gelatin molecules in the films. Likewise, Insulin:gelatin 1:1 ratio also 
showed an increase in the crystallinity regions of the films during the time. Both 
samples, T0 and T30, showed similar peaks around 7.2°, 12.3°, 26.5° and 28.4° 
however with higher intensities for the samples kept in the fridge for 30 days which 
also presented new peaks at 29.40° and 31.68°.  
Overall, all the samples showed changes in the crystalline structure of the 























































































CD results. These events may be due to the fact that the freshly prepared samples 
need time to reach their thermodynamic equilibrium (Abdul-fattah et al. 2007). 
Furthermore, we conclude that the insulin:soluplus 1:1 formulation offered the best 
protective properties to maintain the secondary structure of insulin in its native 
conformation during the time. 
In this sense, insulin:soluplus 1:1 was selected as coating formulation for the 
in vitro release studies. 
3.3.6 Insulin permeation studies 
The permeation profile of insulin from the microneedles coated with 
insulin:soluplus 1:1 was studied using porcine skin and Franz diffusion cells. The 
metallic microneedles were coated with 4IU of insulin and the collected samples 
quantified by HPLC. 
The permeation profile of insulin from the coated MNs are shown in Figure 
3.14. The graph shows that 50% of the dose was released in about 15 min and 80% 
in about 30 min.  
 



































Therefore, the results show that the coated microneedles with 
insulin:soluplus 1:1 allows a relatively fast release of the insulin molecules from the 
coated microneedles and could be potentially used for the treatment of diabetes. 
 Conclusions 
In this study, gelatin and soluplus at different ratios were proposed to 
increase the stability of insulin in the dried state and to be used as coating 
formulations for metallic microneedles. Although, both of them are successfully used 
as stabilizers for many drugs, only soluplus at 1:1 ratio (w/w) presented the ability 
to maintain the most native structure of insulin during the time. The inkjet printing 
provided uniform, precise and reproducible coating layers on the metallic MNs 
without any material loss during the coating process. Furthermore, the permeation 
studies showed that most of the insulin dose permeates the skin within 30 min after 
the MN application. 
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3D PRINTED MICRONEEDLES FOR INSULIN DELIVERY 
 Introduction 
Undeniably, many researchers have shown that coated microneedles can be 
an excellent strategy for transdermal delivery of drugs locally (Gittard et al. 2011; 
Zhang et al. 2012; Baek, Shin and Kim 2017) and systemically (Harvinder S Gill and 
Prausnitz 2007; Ameri et al. 2014; Cormier et al. 2004; Uddin et al. 2015; Boehm et 
al. 2014). Nevertheless, the selection of the materials, the delivery approach and 
the MNs processing are the most important factors that will determine its success. 
Even though many studies have been done with a wide range of materials, 
the metallic microneedles usually offer the best piercing properties due to the 
inherent characteristics of the used materials (Larraneta et al. 2016; Tuan-Mahmood 
et al. 2013). However, the usual two-step administration process, the limited coating 
area, the required time and the fabrication process usually limit the potential 
application of those MNs (Bariya et al. 2012; Kim, Park and Prausnitz 2012) 
3D printing is a family of techniques that have been opportunely applied for 
rapid fabrication of customised pharmaceutical systems (Chimate and Koc 2014; 
Goyanes et al. 2014; Goyanes, Buanz, et al. 2015; Jamróz et al. 2017; Herwadkar 
and Banga 2012; Doraiswamy et al. 2006). Their greatest advantages are the 
capability that those apparatuses have to create unique small and complex objects 
with fine details, with a small time-required process and an easy scale-up production 
(Economidou, Lamprou and Douroumis 2018; Park et al. 2018; Jamróz et al. 2018). 
Recently, different 3D printing technologies have been applied for the 
fabrication of transdermal microneedles. Micro-stereolithography of digital light 
processing (DLP) was used to indirect obtain Gantrez biodegradable microneedles 
from 3D printed moulds (Boehm et al. 2011; Boehm et al. 2013; Boehm et al. 2012). 
In another work, Gittard et al. (2011) directly printed a Class-IIa biocompatible 
polymer MNs arrays through DLP processes to be coated with silver and zinc oxide 
films for antimicrobial attributes. Two-Photon polymerisation (2PP) printers have 
also been applied for the fabrication of hybrid organic-inorganic hollow MNs 
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(Ovsianikov et al. 2007; Doraiswamy et al. 2006). Finally, biodegradable MNs made 
of polylactic acid were directly printed using fused deposition modelling (FDM) 
technology, however the resolution of the FDM printers is still a limiting factor for 
MNs fabrication (Luzuriaga et al. 2018). 
In this sense, different designs of 3D printed MNs made of biocompatible 
material class I approved by FDA and fabricated by Stereolithography were 
combined with inkjet printing technique for the deposition of uniform and accurate 
coatings of a highly dissolvable insulin-sugar formulations for rapid insulin release. 
 Material and methods 
4.2.1 Materials 
Insulin solution from bovine pancreas (10 mg. mL-1) and trehalose dihydrate 
were purchased from Sigma-Aldrich (Gillingham, UK). Xylitol (Xylisorb 90) and 
mannitol (Pearlitol) were donated by Roquette Freres (France). The resin used to 
fabricate the MNs was the biocompatible Class I resin, Dental SG, purchased from 
Formlabs. Streptozocin (≥75% α-anomer basis, ≥98%) and citric acid were both 
purchased from Merck Chemical Co. (Darmstadt, Germany). Saline phosphate 
buffer pH 7.4 was purchased from Sigma-Aldrich. All solvents used were of 
analytical grades.  
4.2.2 3D printing of microneedles 
The microneedles` designs were developed using appropriate engineering 
software (SolidWorks by Dassault Systems) and built on a solid 15x15x1 mm 
substrate. The needles` length and the interspace distance between them 
(measured from tip to tip) were 1.0 mm and 1.85mm, respectively. A Form 2 SLA 
printer with high-resolution capability was used to print the MNs arrays. Following 
the printing, all MNs were washed and cured under UV radiation for 60 min at 40oC 
to improve its mechanical properties. 
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Due to the flexibility of the technique, the number of needles per array can 
be easily changed and straightforwardly printed. Therefore, all printed designs used 
in this work are composed of 48 (6x8) needles per array, unless otherwise stated.  
4.2.3 Penetration studies through porcine skin 
A texture analyser (Stable micro system) was used for the penetration studies 
where the MN arrays were mounted on the bottom of the moving probe using 
double-sided adhesive tape and the porcine skin samples were placed in waxed 
petri dishes at the bottom of the equipment. The probe was then moved at 0.01 
mm/s and the continuous force and displacement measurements were recorded to 
identify the point of needle insertion. 
4.2.4 Coating formulations 
Trehalose, xylitol and mannitol were weighed, added to the insulin solution 
and then left it stirring until complete dissolution. The composition of the coating 
formulations used is shown in Table 4.1. 
Table 4.1. Composition of coating formulations. 
Formulations Composition (w/w) 
Ins:Treh 5:1 10mg Insulin, 2mg Trehalose 
Ins:Treh 3:1 10mg Insulin, 3.33mg Trehalose 
Ins: Xy 5:1 10mg Insulin, 2mg Xylitol 
Ins:Xy 3:1 10mg Insulin, 3.33mg Xylitol 
Ins:Man 5:1 10mg Insulin, 2mg Mannitol 
Ins:Man 3:1 10mg Insulin, 3.33mg Mannitol 
4.2.5 Coating of microneedles through inkjet printing 
The coating process was performed with an Inkjet printing Nanoploter II 
(Gesim, Germany). The MNs were positioned at 45o relative to the dispenser and 
the formulations were jetted through a piezodriven dispenser (pipette) (PicPip 300) 
onto the MN surface in the form of fine droplets of approximately 300 pl. The 
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microneedles were coated through various coating cycles. For each coating array, 
two droplets and 10 spots of a coating formulation were dispensed on each needle’s 
longitudinal axis, and the number of cycles was adjusted to achieve the appropriate 
amount for a required experiment. The coated arrays were then incubated at room 
temperature for 24 hours to allow the evaporation of the solvent (deionised water) 
and the formation of uniform films. 
4.2.6 Scanning electron microscopy (SEM) 
The microneedle arrays were placed on a double-sided carbon adhesive tape 
on top of an aluminium stub. The MNs were then analysed by SEM (Hitachi SU 
8030, Japan) using low accelerating voltage (1.0 kV) to avoid electrical charges on 
the microneedles. The images were digitally taken with different magnifications 
(from 30 to 120x). 
4.2.7 X-ray computed microtomography (μ-CT) 
X-ray computed microtomography scans were performed on pyramid 3D 
printed microneedles coated with insulin:xylitol, insulin:trehalose and 
insulin:mannitol at 5:1 ratios. The analysis was performed using a Bruker Skyscan 
1172, with an SHT 11 Megapixel camera and a Hamamatsu 80kV (100μΑ) source. 
The samples were mounted vertically on a portion of dental wax and positioned at 
259.4 mm from the source. No filter was applied to the X-ray source, and a voltage 
of 80 kV was applied for an exposure time of 1050 ms. Followed the scans of the 
coated arrays, the MNs were inserted in 8-ply strips of parafilm, with an applying 
force of 5 N, to examine the performance of the coatings during piercing and to 
investigate whether any coating material would be detached from the MN and stay 
on the parafilm surface. 
4.2.8 Quantitative analysis of the amount of insulin coated on the MNs 
Pyramid MNs were coated with 10 IU (350µg) of insulin for each 5:1 
formulation ratio in triplicate. The MNs were left to completely dry at room 
temperature for 24 hours and kept in the fridge at 4 °C until the experiment. 
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The coated MNs were individually placed in a glass flask and 8 mL of saline 
phosphate buffer pH 7.4 (PBS pH 7.4) was added to each MN. The vials were placed 
to sonicate for 5min, filtrated and the amount of insulin analysed by HPLC. The 
concentration of insulin was calculated using the analytical curve under the same 
conditions, and the percentage of the coating efficiency (CE%) was then calculated 
with the following equation:  
 
CE (%) = (The amount of insulin analytically determined) x 100  
                            Theoretical amount of insulin  
4.2.9 Circular Dichroism (CD) 
Insulin and insulin-sugar solutions were diluted to 1.0 mg. mL-1 in PBS 7.4 
whereas their respective films were weighed and solubilized in PBS 7.4 to 1.0 mg. 
mL-1 of insulin concentration. All the spectra were recorded at 20 °C between 190 
and 260 nm by CD (Chirascan, Applied Photophysics, UK) using a 0.1 mm 
polarization certified quartz cell (Hellma) and recorded using a step size of 1 nm, a 
bandwidth of 1 nm and an acquisition time of 1 sec. Four scans were recorded for 
each sample, averaged and the corresponding spectrum of water and sugar 
concentration, when required, were then subtracted from each spectrum. For 
estimation of the secondary structure composition of insulin, the CD spectra were 
evaluated by the CDSSTR method (Sreerama, Venyaminov and Woody 1999; 
Sreerama and Woody 2000) using Dichroweb website  (Whitmore and Wallace 
2008; Whitmore and Wallace 2004). 
4.2.10 Raman spectroscopy 
Insulin and insulin-sugar films were analysed using Raman microscopy 
(Jobin Yvon LabRam I) with a laser of 532 nm wavelength coupled with an optical 
microscope with 50x objective. An average of 5 spectra and an acquisition time of 




4.2.11 X-Ray Diffraction (XRD) 
The X-ray diffraction patterns of the films of the raw materials and the films 
of insulin-sugar formulations were obtained using a Bruker D8 Advance (Germany) 
with a Göebel mirror using Cu-Kα radiation and operating at 40 kV and 40 mA. The 
diffractograms were collected in two-theta (2θ) mode from 5° to 40° with a step size 
of 0.02° (2θ) and a counting time of 0.2 seconds per step. 
4.2.12 Stability of Insulin Films  
The stability of the insulin-sugar films was accessed by the study of the films 
through circular dichroism and X-ray diffraction at time zero (T0) and after 30 days 
(T30) kept in the fridge at 4 ± 1 oC. 
4.2.13 Preparation of porcine skin for in vitro release of insulin 
Untreated abdominal porcine skin was obtained from a slaughterhouse 
(Forge Farm Ltd, Kent, UK) and stored at 4° until it was used. The skin was fixed on 
a polystyrene block previously wiped with 70% ethanol. The skin was shaved with 
a razor blade and the fatty tissue below the abdominal skin area was removed with 
a scalpel. Once ready, the skin was then treated with dermatome (Padgett 
dermatome, Integra LifeTMSciences Corporation USA) at an angle of ±45°. The 
thickness of the skin was measured using a calliper, and the tissue samples of 1.0 
± 0.1mm thick were cut at the required dimensions for the Franz diffusion cells. The 
skin samples were then placed onto filter paper soaked in a small amount of PBS 
pH 7.4 for 2 h before use. 
4.2.14 In vitro permeation of insulin through porcine skin 
The transdermal permeation of insulin from the coated MNs through the 
abdominal porcine skin was studied using Franz diffusion cells (PermeGear, Inc., 
PA, USA). The cells were calibrated with PBS pH 7.4 at 6-6.5 mL per hour rate using 
an autosampler (FC 204 fraction collector, Gilson, USA) while the temperature was 
maintained at 37°C using an automated water bath (Thermo Fisher Scientific, 
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Newington, USA). A total diffusion area of 1.1 cm2 was used to access the insulin 
release. 
Each design of MN (pyramid, cone and spear) was coated with 10 IU of the 
three different formulations, insulin:xylitol, insulin:trehalose and insulin: mannitol at 
5:1 ratio (n = 6). The MNs were inserted into the abdominal porcine skin for 30 s 
using manual finger pressure. The pierced skin with the MN was then mounted on 
the donor compartment of the Franz diffusion cells previously equilibrated at 37°C 
with PBS 7.4. Sample fractions were then collected up to 1 h, and the amount of 
insulin was analysed by a validated HPLC method (chapter 2). At the end of the 
experiment, the MNs and the skin were individually placed in a glass flask with 1mL 
of PBS 7.4 and left it to sonicate for 5 min. After that, they were filtrated and analysed 
by HPLC in order to determine any remaining insulin on the MNs or in the skin.  
Statistical analysis for the drug release was performed by using ANOVA (SPSS 
software Inc.), and a 0.05 significance level was adopted.  
4.2.15 Animal studies 
The protocol for the animal experiments were submitted and approved by the 
Research Ethics Committee (reference number 0003/17, Department of Pharmacy, 
Southern University Bangladesh) and conducted according to the Southern 
University Bangladesh policy for the protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes, with implementation of the principle of 
the 3Rs (replacement, reduction, refinement).  
4.2.15.1 Diabetic mice model 
To generate the diabetic animal model, Swiss albino female mice (130 ± 10g) 
were allowed to free access to food and water for 3 days prior to diabetes therapy. 
Streptozotocin (70 mg/kg) in citric acid buffer (pH 4.5) was subcutaneously injected 
on the flank of the animals. To verify the induction of diabetes, fasting blood glucose 
level was measured for each animal at scheduled times using a one-touch 
glucometer (ACCU-CheckVR Active, Roche, Germany). After 7 days of 
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streptozotocin administration, mice with blood glucose exceeding 300 mg/dl were 
considered as diabetic.  
4.2.15.2 Insulin transdermal delivery in diabetic mice 
The diabetic mice were randomly divided into three groups containing 3 mice 
each: (1) untreated group as negative control; (2) subcutaneous injection (SC) (0.2 
IU/animal) as positive control and (3) 3D printed MN coated with Insulin:Xylitol 5:1 
(0.2 IU/animal) as experimental group. 
Preceding the experiment, diabetic mice were anaesthetized and carefully 
shaved at the area of application using an electric razor (Panasonic, USA) 24 hours 
before the experiment. Then, the animals were left for fasting for 12 hours prior to 
the beginning of the study.  
Subcutaneous injection of insulin solution was administered into the dorsal 
skin using a hypodermic needle while the 3D printed MNs coated with insulin were 
applied onto the dorsal skin of the animals, and an adhesive tape (3M, USA) was 
used to prevent any dislodgement during therapy. 
 The microneedles were then removed from the mice skin after 2 hours. For 
all groups, blood samples were collected from jugular vein at 0, 1, 2, 3 and 4 hours 
after the administration and centrifuged at 3000 r.p.m. for 5 min to immediately 
separate the plasma. Plasma glucose levels were measured with a glucometer 
(ACCU-CheckVR Active, Roche, Germany) whereas insulin plasma concentrations 
were determined using insulin ELISA kit.  
4.2.15.3 Pharmacodynamic and pharmacokinetic analyses of insulin 
after application of insulin-3D printed Microneedles 
The minimum glucose level (Cmin) and the time point of minimum glucose 
level (Tmin) were calculated from the respective curves of the blood glucose level 
over time. The relative pharmacological availability (RPA) was calculated with the 
following equation: 
RPA (%) = {(AAC3DMN) × (Dosesc)} / {(AACsc) × (Dose3DMN)} × 100 
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Where AAC3DMN indicates the area above the curve after the application of the 
3D printed MNs, and AACsc shows the area above the curve after the subcutaneous 
injection of insulin.  
The maximum plasma insulin concentration (Cmax) and the time point of 
maximum plasma insulin concentration (Tmax) were calculated from the curve of the 
plasma insulin concentration (µIU/ml) over time curve. The relative bioavailability 
(RBA) was determined using the following equation. 
RBA (%) = {(AUC3DMN) × (Dosesc)} / {(AUCsc) × (Dose3DMN)} × 100 
Where AUC3DMN indicates the area under the curve after the application of the 
3D printed MNs, and AUCsc shows the area under the curve after the subcutaneous 
injection of insulin. 
Furthermore, the comparison of the plasma glucose level and plasma insulin 
level for the SC injection group and the 3D printed MNs group were performed by a 
t-test (SPSS software Inc.), and a 0.05 significance level was adopted. 
 Results and Discussion 
4.3.1 Manufacture and printability of microneedles 
Pyramid, cone and spear MNs were successfully printed using a 
biocompatible resin Class I, FDA approved and a commercial stereolithography 
(SLA) printer, whose laser beam solidifies the resin in a layer by layer manner, 
originating then the 3D structure. The Dental SG resin applied in this work is one of 
the few biocompatible resins that are commercially available and compatible with 
SLA printers and the only Class I compatible with the Form 2 system, which reduces 
the risks of possible side effects caused by the MNs` material. 
4.3.2 Scanning electron microscopy (SEM) of the printed MNs 
From the SEM results (Figure 4.1), it is possible to see that the printer allowed 
the fabrication of the MNs with excellent details. Uniform and reproducible arrays 
were obtained for all pyramid, cone and spear microneedles designs. SEM analysis 
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shows sharp needle tips, revealing the high-resolution capability of the printer and 













Figure 4.1. SEM images of coated 3D printed microneedles (a) and (b) pyramids, (c) and (d) Cones 
and (e) and (f) Spears. 
4.3.3 Penetration of the MN in the porcine skin 
Once the material and the geometry of the microneedles affects the force 
required to pierce the skin (Davis et al. 2004), penetration studies using porcine skin 
were conducted. Similar tests are previously reported in the literature for metallic 
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and polymeric MNs (Donnelly et al. 2012; Pere et al. 2018; McCrudden, Alkilani, 
Cian M. McCrudden, et al. 2014). 
 In this study, all microneedles successfully pierced the skin with no damage 
or failure. Furthermore, the force against displacement data was measured 
throughout the penetration test (Figure 4.2). 
 
Figure 4.2. Force vs displacement curves for MN penetration in the porcine skin. Maximum forces in 
Newton (N) for the MN penetration in the porcine skin: pyramid (2.288N ± 0.23), cone (1.028N ± 
0.04) and spear (3.360N ±0.03) (n=6). 
It is possible to see that all microneedles designs presented a linear 
behaviour at the beginning (displacement < 3.5 mm), however, as the MN continues 
to penetrate the skin, a non-linear connection between the developed forces and 
the penetration depth is revealed. As proposed by Gittard et al. (2013), this 
behaviour indicates that the process of MN penetration in the skin is not a mere 
single event; instead it should be viewed as a series of sequential penetrations.  
As the load increases, the MNs penetrates deeper through the skin until a 
threshold force is reached and the insertion becomes abrupt. At this point, a steep 
drop of the force is observed, indicating that the MN insertion was successful. 
Therefore, the graph shows that cone MN designs require the least force to 
successfully penetrate the skin, followed by the pyramid and spear designs. 
Overall, the SLA technique has been proved to be an attractive process for 
fabrication of identical and reproducible biocompatible MNs with high-resolution 
















material and fast production than other techniques of MNs fabrication (Larraneta et 
al. 2016; Park, Allen and Prausnitz 2005).  
Although all the designed MNs presented excellent results and promising 
applications, the pyramid MN design was selected to be used for transdermal 
delivery of insulin for the animal studies. Its selection was based on the relatively 
small force required to pierce and skin and due to the bigger surface area for coating 
(2.24 mm2) when compared with the cone ones (1.76 mm2). 
4.3.4 Inkjet printing of insulin formulations onto the microneedles 
Inkjet printing is a technology that can be employed for 2D and 3D printing 
purposes (Economidou, Lamprou and Douroumis 2018; Boehm et al. 2014; Singh 
et al. 2010). It this research, it was used to apply the selected formulations onto the 
3D printed MNs once the same technique was successfully used before for coating 
MNs (Ross et al. 2015; Uddin et al. 2015; Boehm et al. 2015; Haj-Ahmad et al. 
2015). 
The dispenser's tip was kept close to the microneedle surface to avoid losses 
of the coating material. Upon voltage appliance, the solution was jetted in the form 
of fine droplets (300 pl) onto the MN surface (Figure 4.3). Due to the flexibility of the 
system, the amount of insulin required for specific tests could be easily adjusted in 
a few clicks by changing the number of dots and cycles required. 
 
Figure 4.3. Inkjet coating process of the 3D printed microneedles. 
The evaluation of the characteristics of the coatings as well as the quality of 
the coating process was accessed by scanning electron microscopy (SEM) and X-
ray computer micro tomography (µCT) as described below. 
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4.3.5 Scanning electron microscopy (SEM) of the coated MNs 
Initially, the coatings of the MNs were analysed for all three MNs` designs 
(Figure 4.4).  It is possible to see that uniform layers were deposited onto the MN`s 
surfaces with high precision and reproducibility. No loss of material in the form of 
satellite droplets on the substrate nor the creation of bulky coatings that are 
observed in conventional techniques such as dip coating could be seen (Haj-Ahmad 
et al. 2015). Moreover, the smooth morphology of the films provided by the 
technique is more likely to prevent losses of the drug during MN insertion, which can 
occur when bulky coatings remain on the skin surface.  
The MN arrays were also measured as having an average and standard 
deviation base, needle height and interspacing between the needles` tips of 
1.06±0.003 mm2, 1.03±0.03 mm2 and 1.84±0.04 mm2 respectively, which are very 
close to the designed dimensions. 
 (a) (b) (c) 
   
Figure 4.4. SEM images of coated 3D printed microneedles (a) pyramid, (b) Cone and (c) Spear. 
4.3.6 X-ray computed microtomography (µ-CT) 
The coated microneedles and the performance of the coatings during 
piercing were also investigated by µ-CT. 
A total of 962 µCT images were taken in 0.2o steps around one hemisphere 
of the sample with an average of 4 frames taken at each rotation step. The images 
generated were 2664 x 4000 pixels with a resolution of 6.75 μm per pixel, which 
were reconstructed by Bruker’s CTvol software. 
Figure 4.5 (a) shows an overview of the inkjet coatings onto a printed pyramid 
microneedle. A coffee ring effect in the density of the coating material deposition 
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was noticed for all coated samples and a fringe layer of 10-15µm was more 
pronounced for insulin: xylitol coatings (b). Furthermore, the relative density of all 





Figure 4.5. µ-CT scan of the coated pyramid microneedles (a) superior overview and (b) cross-
section overview. 
Scans were taken from the side and the back of the coated MNs (Figure 4.6) 
presented thin coated layers for all insulin-sugar formulations being in accordance 
with previous SEM data.  
 
 
Figure 4.6. µ-CT images of (a) the back and (b) the side of the pyramid microneedle arrays. 
The performance of the coatings during the piercing was accessed through 
a penetration experiment where a 5 N force was applied on the base of the coated 
MNs against 8-ply strips of parafilm. The cross-section of the pierced strips (Figure 
4.7) demonstrates that the films stay on the MNs surfaces during the piercing. 
Furthermore, the averaged depth measured for all pyramid MNs was 650mm which 




Figure 4.7. µ-CT image of a cross-section of MN array penetration through an 8-ply strip of parafilm. 
Overall, inkjet printing demonstrated to be a powerful technique for precise 
and reproducible coating method for 3D printed MNs. Furthermore, the coatings 
provided by this technique demonstrated to be very thin and stay on the MN surface 
during piercing with no loss during the process. 
4.3.7 Quantitative analysis of the amount of insulin coated on the MNs 
The amount of insulin coated on the MNs (10 IU) was quantified by HPLC 
and the analytical concentration was calculated using the calibration curve (Table 
4.2). 
Table 4.2. Coating efficiency of insulin-sugar formulations using inkjet printing method. 
 
From the results, it is possible to see that inkjet printing is a reliable method 










Ins:Trehalose 350.00 345.20 ± 4.14 98.63 ± 1.18
Ins:Xylitol 350.00 342.53 ± 4.56 97.89 ± 1.30
Ins:Mannitol 350.00 352.34 ± 4.82 100.67 ± 1.37
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4.3.8 Characterisation of insulin-sugar formulations 
4.3.8.1 Circular Dichroism 
Circular dichroism (CD) spectroscopy can be used to study the secondary 
structure conformation of a molecule in a sample, giving important information about 
protein denaturation and protein-ligand interactions (Kelly, Jess and Price 2005). 
Accordingly, in this research, CD was used to investigate the effect of different 
sugars on the insulin structure as well as its stability.  
The spectrum of pure insulin (Figure 4.8) at 1.0 mg/mL in PBS 7.4  shows 
two minima peaks around 210 and 222 nm associated with α-helix and β–sheet, 
respectively, which are in accordance with previous studies (Ettinger and Timasheff 
1971; Sarmento et al. 2007; Andrade et al. 2015).  
 
Figure 4.8. CD spectrum of insulin solution at 1.0 mg/mL in PBS 7.4. 
Insulin and insulin-sugar solutions were analysed to understand the 
conformational behaviour of insulin in those systems, especially in the presence of 
sugars. The spectra of insulin, insulin-xylitol (Ins:Xy), insulin-trehalose (Ins:Treh) 
and insulin-mannitol (Ins:Man) in solution (Figure 4.9) were found to be quite similar 
showing two negative minima around 210 and 222 nm which is a typical 
predominant feature of α-helix structures as already reported in the literature (Wu 
and Yang 1981; Ettinger, Timasheff and Strycharz 1971; Correia et al. 2012). 
Moreover, the estimation of insulin content by CDSSTR is quantitatively 


























    
Figure 4.9. CD spectra of insulin and insulin-sugar formulations in solution at different ratios (w/w) at 
1.0 mg/mL in PBS 7.4. 
 
Table 4.3. Percentage of secondary structure estimation of insulin and insulin formulations in solution 
at different ratios (w/w). 
 
The CD spectra and the estimation of the secondary structure of insulin 
suggest that the sugars, in solution, do not alter the secondary structure of insulin 
which showed to be very similar to the pure insulin solution. It is likely that xylitol, 
trehalose and mannitol in solution possess a similar effect on the hydrogen bond 
network of water for all concentrations analysed in this work. Similar results were 
also found for different concentrations of trehalose, sucrose and maltose solutions 
below 30% (Lerbret et al. 2005). 
It is well known that in aqueous solution proteins are preferentially hydrated, 
which helps to maintain their three-dimensional structure. In the presence of sugars, 
such as trehalose, the water network is disrupted, and strong hydrogen-bonds are 
created between trehalose and water (Branca et al. 2005; Lerbret et al. 2005; 
Ohtake, Kita and Arakawa 2011). Therefore, it is suggested that sugars do not 






























5:1 3:1 5:1 3:1 5:1 3:1 
α-helix 51 50 49 49 49 49 49
β-sheet 11 10 11 13 10 12 11
Turn 9 10 11 13 11 11 12
Random coil 30 29 30 25 28 27 28
Insulin (%)
Ins:Xy (%) Ins:Man (%) Ins:Treh (%)
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hydrated shell around proteins protecting them (Jain and Roy 2009; Castro et al. 
2015). 
Figure 4.10 shows the CD spectra of insulin solution in comparison with the 
respective films of insulin solution and insulin-sugar formulations at 1.0mg/mL. All 
the samples display similar CD spectra showing two minima peaks around 210 and 
222 nm, which are associated with α-helix and β-sheet content. 
 
 
Figure 4.10. CD spectra of insulin solution, insulin film and insulin-sugar films at different ratios (w/w) 
at 1.0 mg/mL in PBS 7.4. 
The pure insulin film showed a notable reduction in the Molar ellipticity 
(Figure 4.10) accompanied by changes in the spectra. It was noted that the 
dehydration led to a decrease in α-helix content of insulin whereas the β-sheet and 
turn structures were raised (Table 4.4). Analogous results were found by Zeng et al. 
(2011) upon insulin dehydration where relative humidity (RH) was decreased from 
92% to 2%. 
 

































5:1 3:1 5:1 3:1 5:1 3:1 
α-helix 51 47 52 54 48 49 48 49
β-sheet 11 15 20 12 14 8 16 13
Turn 9 15 9 12 14 9 11 11





Ins:Xy film (%) Ins:Treh film (%) Ins:Man film (%)
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The depletion of the α-helix content of insulin was also reported by Andrade 
et al. (2015) after lyophilisation. Even though air-drying was used in this study with 
the advantage of avoiding the potential damaging stress of freezing, it is possible 
that some insulin molecules may undergo aggregation and irreversible unfolding 
when dried alone. 
Overall, it is well known that the protective mechanism of sugars in a solution 
state is very different from a dried state, once the surrounded water is partially or 
completely removed during dehydration (Cicerone, Pikal and Qian 2016; Carpenter 
and Crowe 1989). Accordingly, the water replacement mechanism is the most 
accepted theory that tries to explain the mechanism behind the ability of sugars to 
protect biomolecules in a dried state (Carpenter and Crowe 1989; Haque et al. 
2015). Therefore, it is suggested that during the dehydration process, sugars may 
substitute water molecules around the biomolecules of proteins, maintaining its 
three-dimensional structure by providing sites with hydrogen-bonding species 
(Carpenter and Crowe 1989; Branca et al. 2005; Jain and Roy 2009).  
Considering that, it is also possible to see that all insulin-sugar films (Figure 4.10 and Table 4.4 
Table 4.4) tend to better maintain the α-helix structure of insulin in the dried 
system when compared to the dried insulin alone. Interestingly though, xylitol 
presented the most effective protective properties of all sugars, leading to even 
higher amounts of α-helix content than the native insulin itself. However, the reason 
for that remains unclear and further studies are needed.  
4.3.8.2 Raman Results 
In this study, the spectrum of the native of insulin (Figure 4.11) shows a 
strong peak of amide I band at 1661 cm-1 and a shoulder near 1682 cm-1 assigning 
the α-helix structure and the random coil form, respectively. Amide III bands are 




Figure 4.11. Raman spectrum of pure insulin film. 
All insulin formulations showed similar Raman spectra (Figure 4.12) to the 
native insulin, and distinctive peaks of sugars were not found in Raman spectra 
mainly due to the fact that insulin was more concentrated than the sugars in the 
films. Furthermore, the amorphous nature of the films (see XRD data) does not 
afford a strong Raman signal. 
 
 
Figure 4.12. Raman spectra of insulin and insulin-sugar formulations. 
The spectra show amide I band of insulin-xylitol and Insulin-mannitol 5:1 ratio 
(w/w) with peaks at about 1662 cm-1 whereas insulin-trehalose 5:1 ratio was shifted 
to 1658 cm-1. Diversely, when the sugar concentration was increased to 3:1 ratio, 
the amide I band position of insulin-trehalose and insulin-xylitol was shifted to 1663 
cm-1 and 1665 cm-1, respectively, while insulin-mannitol was shifted to 1660 cm-1. 
Those changes were also reported by Carpenter and Crowe (1989) and Souillac 
(2002) and might be due to both the concentration and the different effect of each 






























sugar on the vibrational spectra of insulin regarding the hydrogen bonding and 
couplings between the adjacent peptide units.  
Amide III is also an important feature for analysing the secondary structure 
of proteins. From the spectra, it is possible to see that the amide III bands are wider 
and unresolved compared to the pure insulin spectrum, especially for insulin:xylitol 
3:1 sample. Similar results were reported by Zeng et al. (2011) where they have 
demonstrated that amide III and I bands tend to be unresolved and broadened as 
the dehydration increases. 
The disulphide bonds are very sensitive to conformational changes and so it 
plays an important role in determining and establishing the folded structure of insulin 
(Zeng et al. 2011). From the spectra, it can be seen that for insulin and insulin 
formulations, the S-S stretching vibration bands are located close to 510 cm-1 
suggesting that all disulphide bonds are in the most stable conformation of gauche 
gauche-gauche with its hydrophobic surfaces buried in its three-dimensional 
structures as a result of a great water removal. 
Raman bands of Tyrosine (Tyr) residues are very sensitive to the 
environmental changes in proteins, especially in the dehydration process. The 
Raman spectra show Tyr peaks at about 642, 828, 852, 1174 and 1206 cm-1, with 
the last being related to both Tyr and Phenylalanine residues. Tyr doublet located 
at ~830 and ~850 cm-1 is the strongest and the most important band of Tyr features 
for the protein structure determination. Furthermore, the relative intensity ratios of 
Tyr residues of I850/I830 and I1174/I206 are sensitive to the environment and the 
property of the hydrogen bonding (Zeng et al. 2011).  
In the research, the Tyr doublet appeared at about 828 and 852 cm-1, and the 
intensity ratios of I852/I828 and I1174/I1206 obtained varied from 0.91 to 1.05 and 0.73 
to 0.90 respectively (Table 4.5). From the table, it is possible to see that the I852/I828 
values indicate that tyrosine residues tend to be more exposed and establish more 
hydrogen bonds in the presence of sugars as the intensity ratio increases. 
Furthermore, most of the films showed an increase in the I1174/I1206 ratios indicating 
further retention of the molecules of water in the films. Interesting though, insulin-
xylitol 3:1 showed the lowest I1174/I1206 values, suggesting even greater dehydration 
than pure the insulin film, along with a stronger hydrogen-bonding interaction.  
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Table 4.5. Relative intensity of Tyr residues of insulin and insulin-polymer films at different ratios 
(w/w). 
 
Overall, the presence of the sugars in the films tends to reduce the number 
of water molecules that are lost during dehydration and increase the hydrogen-
bonds of Tyr residues. Therefore, these results also agree well with many other 
studies that have demonstrated the formation of hydrogen-bonds between 
carbohydrates and many dried proteins, supporting the stabilisation theory by the 
water replacement mechanism (Carpenter and Crowe 1989; Crowe, Reid and 
Crowe 1996; Prestrelski et al. 1993; Jovanović N, Bouchard A, Hofland GW, 
Witkamp GJ, Crommelin DJ 2006). 
4.3.8.3 X-ray diffraction (XRD) 
Insulin-sugar films and the films of the pure components were studied by X-
ray analysis. The diffractograms were recorded to understand the nature of the films. 
From Figure 4.13, it is possible to see that insulin exhibited predominant amorphous 
state with a small peak at 31.79° whereas the sugars’ films are prone to crystallise 
under the same air-drying conditions.  
The diffractogram of xylitol showed distinctive peaks at 13.98°, 19.81°, 
22.22°, 24.74°, 31.6°, while trehalose displayed singular peaks at 12.70°, 13.75°, 
14.64°, 15.38°, 16.62o, 17.01°, 21.21° and 23.94°, both identified in its dehydrated 
form. Diferently, the main peaks of mannitol are displayed at 9.78°, 17.36°, 20.51°, 
22.22° and 24.79°, which are related to the three polymorphs of mannitol.  
Insulin Ins:Xy 5:1 Ins:Xy 3:1 Ins:Treh 5:1 Ins:Treh 3:1 Ins:Man 5:1 Ins:Man 3:1
I852/I828 0.91 0.97 1.05 0.92 1.00 1.02 1.00
I1174/I1206 0.77 0.79 0.73 0.81 0.90 0.79 0.89
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Figure 4.13. Diffractograms of the films of the formulation's components: (a) insulin, (b) xylitol, (c) 
trehalose and (d) mannitol. 
Figure 4.14 shows the diffractograms of insulin-sugar films. Overall, all the 
films are predominantly amorphous. Ins:Xy did not show any sign of crystallisation. 
Ins:Man 3:1 displays a peak at 31.71o possible due to insulin contribution while 






















































































Figure 4.14. Diffractograms of the insulin-polymer films at different ratios (w/w). (a) insulin:xylitol, (b) 
insulin:trehalose and (c) insulin:mannitol 
It is interesting to note that even though the studied sugars show a highly 
tendency for crystallisation when air-dried alone, in the presence of insulin, xylitol, 







































































reported in the literature for many different sugars and proteins (Pierre O. Souillac, 
Middaugh and Rytting 2002; Pierre O Souillac, Middaugh and Rytting 2002; Górska 
et al. 2017). 
Izutsu et al. (1994) have studied the stability of different proteins by 
amorphous and crystallised mannitol. They found that amorphous mannitol 
preserved L-lactate dehydrogenase and other proteins under freeze-drying 
conditions while its crystalline form had no protective effect on them (Izutsu, Ken-
ichi; Yoshioka, Sumie; Terao 1994). Similar protein protection was also found for 
amorphous matrixes of trehalose (Imamura et al. 2003; Pierre O. Souillac, Middaugh 
and Rytting 2002; Górska et al. 2017). Although xylitol has not been greatly explored 
for protein stabilisation yet, in this study, amorphous xylitol presented good 
stabilisation of insulin during drying and even promoted the assembly of its α-helix 
structure. 
The advantage of amorphous systems on the stabilisation of proteins has 
been reported in several studies. (Faghihi et al. 2016; Pierre O. Souillac, Middaugh 
and Rytting 2002). In fact, the formation of an amorphous matrix during dehydration 
showed to be crucial for many protein stabilisations such as LDH, Escherichia coli, 
B-galactosidase and L-asparaginase, rh-DNase (Izutsu, Ken-ichi; Yoshioka, Sumie; 
Terao 1994; Pierre O Souillac, Middaugh and Rytting 2002). 
Overall, the insulin-sugars formulations investigated in this research 
originated predominantly amorphous films, which is known to be more stable for 
insulin than the crystalline ones (Pikal, M. J.; Rigsbee 1997). 
4.3.9 Insulin stability  
The stability of insulin and insulin-sugar films were studied by Circular 
Dichroism and X-ray diffraction using the same parameters as before. The samples 
were analysed at time zero (T0) and after thirty days (T30) kept in the fridge at 
4oC±1. 
Figure 4.15 compares the CD spectrum of insulin at T0 and T30. Both 
samples showed double minima around 210 and 222 nm at both times, which are 
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related to α-helix and β–sheet content structures of the native insulin. Furthermore, 
the estimation of the secondary structure of insulin is summarised in Table 4.6. 
 
Figure 4.15. CD spectra of insulin film at time zero and after 30 days. 
 
Table 4.6. Percentage of the secondary structure of insulin solution, insulin film and insulin-sugar 
films at different ratios (w/w) at 1.0mg/mL in PBS 7.4. 
 
From the insulin spectra, it is possible to see a small change in the spectra 
with a decrease in the Molar ellipticity intensity of insulin during the time, signalling 
a decrease in alpha-helix content. Exploring further, according to the secondary 
structure estimation, the data indicate that insulin loses some of its α-helix structure 
during the time while some β-sheets structures are formed. 
Figure 4.16 compares the CD spectra of the insulin-sugar formulations at T0 
and T30 with the CD spectrum of insulin at T30 without any sugar protection. 
Overall, all the samples at both times also showed double minima around 210 and 
222 nm, characteristic of helix and β–sheet structures, which agrees with the 
literature (Sarmento et al. 2007). Furthermore, the percentage of insulin content was 































T0 T30 5:1 3:1 5:1 3:1 5:1 3:1 5:1 3:1 5:1 3:1 5:1 3:1 
α-helix 47 45 52 54 54 52 48 49 49 49 48 49 47 47
β-sheet 15 21 20 12 10 14 14 8 10 9 16 13 22 21
Turn 15 12 9 12 9 9 14 9 12 9 11 11 12 13
Random coil 22 23 18 21 27 25 24 34 29 34 24 26 20 19
Ins:Man T0 (%) Ins:Man T30 (%)Insulin (%) Ins:Xy T0 (%) Ins:Xy T30 (%) Ins:Treh T0 (%) Ins:Treh T30 (%)
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                                                             e
 
                                                             f 
 
Figure 4.16. CD spectra of insulin and insulin-sugar formulations at 1.0 mg/mL in PBS 7.4 at T0 and 
T30. 
All sugars tested in this study showed a good capability to protect insulin from 
denaturation during the time kept in the fridge at 4 °C. From the spectra and the 
estimation of the secondary structure of insulin in the films (Figure 4.16 (a) and (b) 

























































































































































content increased slightly during the time from 52% to 54% followed by a decrease 
in β-sheet structures whereas Ins:Xy 3:1 ratio showed the opposite behaviour. 
The CD spectra of Ins:Treh films showed almost the same amount of α-helix 
content at both times, T0 and T30. After thirty days, the 5:1 sample presented a 
decrease in the β-sheet structures whereas an increase of the random coil forms 
was noticed for the 3:1 film. Furthermore, Ins:Man films presented a tendency for 
losing α-helix content and increasing β-sheets structures during the time. 
Overall, CD results show that all the studied sugars provided good insulin 
protection with xylitol showing the best results followed by trehalose and mannitol. 
However, neither the concentration nor the peculiar role of each sugar on the 
secondary structure of insulin can be explained based on what it is known until now 
once the mechanisms involved on sugar-protein protection are not entirely 
understood as previously discussed. 
As mentioned earlier, the stability of the samples was also analysed by X-ray 
diffraction, and the results and discussion are shown below. 
The diffractograms of insulin films at T0 and T30 (Figure 4.17) revealed the 
predominant amorphous nature of insulin during the time. From it, it is possible to 
see that insulin T0 shows a small peak at 2θ = 31.79° whose intensity increases and 
shifts during the time to 31.66° (insulin T30). Furthermore, it is also possible to see 
the formation of a small peak at 28.33° for the insulin T30, which might indicate the 
growth of the small crystalline regions of insulin during the time. 
 
















Insulin T0 Insulin T30
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Figure 4.18 shows the diffractograms of insulin-sugar formulations at T0 and 
T30. Both ratios of Ins:Xy films showed no crystalline peaks at T0, indicating an 
amorphous nature of the system. After 30 days, Ins:Xy 5:1 showed a peak at 28.39° 
while Ins:Xy 3:1 displayed a small peak at 28.33°. Once those peaks are 
characteristic of insulin, they may indicate crystallisation sites of insulin inside of the 
amorphous matrix during the time.  
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The diffractogram of Ins:Theh 5:1 T0 showed a predominance of amorphous 
nature with 3 peaks at 8.92°; 29.54° and 31.83°, which resolved into two peaks at 
27.75° and 28.39° after thirty days. Likewise, Ins:Treh 3:1 appears to have the same 
tendency to form crystalline regions on the film matrix during the time. In this sense, 
Ins:Treh 3:1 changes from a typical amorphous phase with no crystalline peaks at 
T0 to a predominant amorphous phase with some sites of crystallinity with peaks at 
28.31° and 29.30°. 
The XRD patterns of Ins:Man films also showed a typical predominance of 
amorphous phase with formation of some crystalline sites during the time. At 5:1 
ratio T0, the Ins:Man diffractogram displays a small peak at 28.33° which increases 
after 30 days. Additionally, a new small peak is formed at 31.71° for Ins:Man 5:1 
T30. In the same way, Ins:Man 3:1 T0 showed a peak at 31.71° while the analysis 
after thirty days showed the formation of two peaks at  20.26° and 28.27°. 
As well pointed by Abdul-fattah et al. (2007), once the thermodynamic 
equilibrium of the freshly prepared amorphous systems is not reached, there is a 
tendency for many amorphous solids to either crystallise or at least slowly ‘‘relax,’’ 
in order to restore the system to equilibrium. In this sense, it is possible that the 
obtained insulin-sugar films were not in equilibrium at T0 which could explain the 
changes on the diffractograms during the time. Ultimately, all insulin-sugar 
formulations presented predominant amorphous matrix even after 30 days which is 
known to be essential for protein stabilisation as discussed before (Abdul-fattah et 
al. 2007). 
From the stability studies, all the insulin-sugar formulations studied provided 
good insulin protection with xylitol showing the best protective properties followed 
by trehalose and mannitol. Thereby, once the 5:1 insulin-sugars ratio presented the 
best stability performance, they were selected as coating formulations for the 3D 
printed microneedles and further studies were done. 
4.3.10 Insulin permeation studies 
The in vitro permeation profile of insulin from the three different formulations 
(Ins:Xy, Ins:Treh and Ins:Man at 5:1 ratio) and the three different MNs designs 
(pyramid, cone and spear) were studied using porcine skin and Franz diffusion cells. 
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The 3D-printed MNs were coated with 10 IU of insulin and the collected sample 
fractions quantified by HPLC method.  
Figure 4.19 shows the cumulative permeation profile of insulin from the 
coated MNs (n=6). From the graphs, it is possible to see that pyramid MNs (a) 
showed insulin permeation variation rates from 63 to 69% in the first two minutes 
while cone (b) and spear (c) designs showed variations about 57 to 64% and 62 to 
70%, respectively. Despite of that, approximately 85 to 95% of insulin permeated 
from all coated MNs in 30 min and no statistical difference was noted among the 
carriers nor the MNs (ANOVA, p>0.05). 
The used carriers not only preserved insulin in its native form but also 
provided fast permeation rates which is attributed to the hydrophilic nature of the 
sugars as well as the thin coating layers onto the MNs (10-15µm) as shown from 









Figure 4.19. In vitro permeation profile of insulin from 3D printed MNs designs (a) pyramid MNs, (b) 
















































































































4.3.11 Insulin transdermal delivery in diabetic mice 
After 7 days from streptozotocin administration, the animals presented 
hyperglycaemia levels of 340 ± 10 mg/dl, confirming a successful diabetes 
induction.  
The 3D printed microneedles coated with 0.2 IU of insulin (1.206 µmolar) 
were applied on the shaved skin of the mice and additionally secured with adhesive 
tape. To compare the delivery efficiency of the microneedles, 3D printed MNs 
coated with 0.2 IU of insulin per array were applied on the back of the animals 
whereas 0.2 IU of insulin was subcutaneously injected into mice as positive control. 
Untreated mice were used as the negative control. Figure 4.20  shows the 
application process of the 3D printed MN arrays on the animals.   
 
Figure 4.20. Experimental mice during application of the 3D printed MN array for insulin delivery. 
To avoid hypoglycemia in mice for 4h, a 0.2 IU dose was selected and the 
comparative plasma glucose levels and insulin concentration vs time for the three 
different delivery strategies are shown as follows. 
As expected, a quick reduction in plasma glucose level within one hour can 
be seen after insulin subcutaneous injection (Figure 4.21 and Table 4.7). Interesting 
though, 3D printed MNs arrays loaded with insulin also showed a similar initial 
profile, presenting a maximum decrease in glucose levels after one hour of being 
administered. The minimum glucose level (Cmin) for both treatments was about 30% 
of its initial level, and they did not show any statistical difference. This rapid decrease 
in glucose level for the experimental group indicates the high efficiency of the 3D 
printed MNs coated with insulin which is consistent with the in vitro transdermal 




Figure 4.21. Comparative plasma glucose level for untreated group, subcutaneous (SC) injection 
and 3D printed MNs coated with insulin in international units (IU) (n=3). 
 
Table 4.7.Pharmacodynamic parameters for plasma glucose levels of diabetic mice for untreated 
groups, subcutaneous (SC) injection (insulin dose: 0.2 IU) and 3D Printed MN array (insulin dose: 
0.2 IU) (n=3). 
 
Cmin, minimum glucose level; Tmin, time point of minimum glucose level; AAC0 to 4, area above 
the plasma glucose concentration vs. time curve; RPA, relative pharmacological availability 
compared to subcutaneous injection.  
Previous studies with MNs also have attained similar blood glucose level 
profiles in the first hour (Ito et al. 2006; Qiu et al. 2012; Yu, Jiang, Liu, et al. 2017). 
In this study though, after a Cmin had been reached, a steady state plasma glucose 
level continued to be maintained at a low level for 3 h after administration of the 3D 
printed MNs. These findings suggest that insulin is being released from the MNs to 
the mice bloodstream via passive diffusion. Furthermore, the blood glucose level for 
the untreated group is kept stable and maintained around 340±10 mg/dL. No 
hypoglycemia effect were observed for any group for the same period. 
Figure 4.22 and Table 5.8 show the pharmacokinetic parameters of the 
plasma insulin levels for the three groups. As shown, the peak value of insulin 
Group Cmin (%) Tmin (h) AAC0-4(%h) RPA(%)
No treatment 89.5 3 26.65 0
Insulin SC 32.8 1 208.45 100
Insulin loaded 3D printed MNs 30.1 1 240.75 122
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concentration for SC injection is reached in a short period of time (1h). A similar 
initial profile was also noticed for the 3D printed coated MNs group with the same 
amount of insulin. Even though the Cmax of the SC injection group presented to be 
slightly higher than the 3D printed MNs group, statistical analysis did not show any 
difference between the groups at time 1h. The control group did not show any 
detectable insulin in the plasma. 
 
Figure 4.22. Comparative plasma insulin concentration for untreated group, subcutaneous (SC) 
injection and 3D printed MNs coated with insulin in international units (IU) (n=3). 
 
Table 4.8. Pharmacokinetic parameters for plasma insulin concentrations of diabetic mice for 
untreated groups, subcutaneous (SC) insulin injection (0.2 IU) and 3D Printed MN array coated with 
insulin (0.2 IU) (n=3). 
 
Cmax, maximum plasma insulin concentration; Tmax, time point of maximum plasma insulin 
concentration; AUC0 to 4, area under the plasma insulin concentration vs. time curve; RBA, relative 
bioavailability compared with subcutaneous injection. 
Comparatively, Zhang and co-workers (2018) studied the pharmacokinetic 
parameters of SC injection of insulin (10 IU) and 3 different insulin concentrations 
using a dissolvable alginate/maltose composite MNs (5, 10 and 20 IU). They found 













No treatment 0 0 0 0
Insulin SC 63.2 1 120.5 100
Insulin loaded 3D printed MNs 59.9 1 147.41 115
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reached the peak of insulin concentration in one hour, altogether with the SC 
injection. Furthermore, their results showed that the level of serum insulin is dose-
dependent and even the Cmax for dissolvable MNs loaded with 5 or 10 IU are lower 
than the SC injection which suggests that insulin from the dissolvable MNs requires 
more time for permeation and diffusion to the bloodstream.  
Similar pharmacokinetic behaviour was also reported for different 
biodegradable MNs by Liu et al. 2012, Yu et al. 2017 and Lee et al. 2017 whereas, 
for other dissolvable MNs, the maximum plasma insulin concentration was attained 
in 2 hours or more (M. Ling and Chen 2013; Yu, Jiang, Zhang, et al. 2017). These 
results suggest that the formulation of the MNs plays an important role in the release 
of the drug as well as in the passive diffusion to the blood capillarity and therefore 
in the insulin bioavailability. 
Differently from previous studies though, the concentration of insulin is 
maintained at a steady rate about 50% of its maximal concentration for the 3D 
printed MNs coated with insulin. This event supports the hypothesis that after the 
insertion of the MNs, the insulin is absorbed to the blood capillarity by passive 
diffusion.  
Finally, our research also showed that the relative pharmacological 
availability (RPA) and the relative bioavailability compared with subcutaneous 
injection (RBA) for insulin loaded on the 3D printed MNs group were about and 122 
and 115 %, respectively, compared with SC injection. These results indicate that 
insulin released from 3D printed MNs was almost completely absorbed from the skin 
into the systemic circulation, and the pharmacological activity of the released insulin 
remained intact after the delivery with the 3D printed MNs. 
 Conclusions 
The desktop 3D printer stereolithography, Form 2, used in this research is a 
low-budget printer that demonstrated an exceptional ability for rapid and versatile 
fabrication of reproducible microneedle arrays with high quality for all proposed 
designs, pyramid, cone and spear. Although the mechanical properties of the 
biocompatible MNs need to be further explored, the preliminary studies with the 
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piercing properties indicate that the biocompatible resin has good mechanical 
properties and the 3D printed MNs requires low forces to penetrate the skin. 
The insulin-sugar formulations presented in this study demonstrated that 
xylitol, trehalose and mannitol can provide good insulin protection for coated MNs 
with xylitol showing the best insulin stabilisation performance. The coating method 
used to coat the 3D printed MNs demonstrated that inkjet printing was successfully 
used for the application of insulin-sugar formulations on the surface of the 
microneedles. The results showed that this technology delivered highly uniform, 
reproducible and accurate coatings on the microneedles. 
In vitro studies revealed that all the carriers showed rapid insulin release 
rates within 30 min. Further studies with diabetic mice confirmed the fast insulin 
release from the microneedles with a rapid decrease to the plasma glucose levels 
within one hour like SC injection group. However, differently from the SC injection 
group, after insulin had reached its peak, the plasma insulin concentration is 
maintained at a steady state rate at about 50% of its maximal concentration for three 
hours, probably due to the passive diffusion event. 
Overall, the fast fabrication of biocompatible MNs through stereolithography 
combined with an accurate coating method using inkjet printing and the use of highly 
dissolvable and stable coatings have been demonstrated to be an exciting strategy 
for rapid release of insulin. 
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5  CHAPTER 
ANIMAL STUDIES 
 Introduction 
Since it was discovered in the 1920s, exogenous insulin therapy has helped 
to improve the quality of life of many people as well as save many people's lives. 
The first insulins available for commercial use were extracted from bovine and 
porcine pancreas. However, a strong immune response was very common due to 
their impurity and therefore other alternatives started to be studied. 
Due to the advance in the field of genetic engineering, in the 1980s the 
human proinsulin gene was inserted into a bacterium's gene by recombinant DNA 
technique and started to be produced by cultures of bacteria (Saccharomyces 
cerevisiae and by a non-pathogenic strain of Escherichia coli). Since then, many 
modifications in the human insulin structure have been proposed and many insulin 
analogs are now available on the market. 
Once insulin therapy aims to mimic the physiologic pattern of insulin 
secretion, short-insulin analogs were designed for bolus insulin therapy to control 
postprandial hypoglycemia whereas intermediate and long-acting insulin analogs 
were proposed to simulate the basal insulin secretion. While it is not possible yet to 
achieve both patterns with only one insulin analog, the combination of short with 
intermediate or long-acting insulin is very common. 
Despite the advances in the genetic engineering and drug delivery fields, the 
administration of insulin through oral route is still a challenge and the subcutaneous 
injections remains the most common alternative. 
 The promising results described in the previous chapter have suggested that 
the 3D printed microneedles coated with bovine insulin-xylitol showed good insulin 
stability and the same effectiveness as the subcutaneous injection in reducing 
blood-glucose levels. Therefore, in this study, a short and long-acting insulin therapy 




 Materials and methods 
5.2.1 Materials 
Insulin aspart (Novolog) and insulin glargine (Lantus) were commercially 
available. Xylitol powder (Xylisorb 90) was donated by Roquette Freres (France). 
The streptozocin and citric acid were both purchased from Merck Chemical Co. 
(Darmstadt, Germany). Phosphate buffer PBS 7.4 was purchased from Sigma-
Aldrich. The resin used to fabricate the MNs was the biocompatible Class I resin, 
Dental SG, purchased from Formlabs. All the solvents used were of analytical 
grades.  
5.2.2 Coating formulations  
Xylitol was weighted and added to either the insulin aspart or glycine solution 
at 5:1 ratio (w/w). The solution was left it stirring until complete dissolution. 
5.2.3 Coating microneedles through inkjet printing 
The 3D printed microneedles with pyramid design containing 48 
needles/array was selected for this study. The printing and the coating process 
follow the same procedure described in chapter 4. For each coating array, two 
droplets of 10 spots of the coating formulation were dispensed on each needle's 
surface. A total of 7 and 18 layers were dispensed on the 0.2 and 0. 5 IU MN arrays, 
respectively. The coated MNs were left at room temperature for 24h to allow the 
evaporation of the water and formation of uniform films. 
5.2.4 Animal studies 
The protocol for the animal experiments were submitted and approved by the 
Research Ethics Committee (reference number 0008/18, Department of Pharmacy, 
Southern University Bangladesh) and conducted according to the Southern 
University Bangladesh policy for the protection of Vertebrate Animals used for 
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Experimental and Other Scientific Purposes, with implementation of the principle of 
the 3Rs (replacement, reduction, refinement).  
5.2.4.1 Diabetic mice model 
Swiss albino female mice (130 ± 10 g) were allowed to free access to food 
and water for 3 days prior to diabetes therapy. To generate the diabetic animal 
model, Streptozotocin (70 mg/kg) in citric acid buffer (pH 4.5) was subcutaneously 
injected on the flank of the animals and the blood glucose levels were daily 
monitored at specific times using a one-touch glucometer (ACCU-CheckVR Active, 
Roche, Germany). After 7 days of streptozotocin administration, mice with blood 
glucose exceeding 300 mg/dl were considered as diabetic.  
5.2.4.2 Insulin transdermal delivery in diabetic mice 
Twenty-four hours before the experiment, the animals were anesthetized with 
pentobarbital and carefully shaved using an electric razor (Panasonic, USA). 
Followed that, the animals were left for fasting for 12 hours prior to the beginning of 
the experiment. 
For each insulin analog (aspart or glargine), the diabetic mice were randomly 
divided into five groups (n = 5 for each group): (1) negative control: uncoated MNs; 
(2) Positive control 1: subcutaneous injection of insulin with 0.2 IU/animal; (3) 
Positive control 2: subcutaneous injection of insulin with 0.5 IU/animal; (4) Coated 
MNs with 0.2 IU/animal of insulin:xylitol 5:1 (w/w)  and (5) Coated MNs with 0.5 
IU/animal of insulin:xylitol 5:1 (w/w). 
For the positive control groups, the animals received subcutaneous injection 
of insulin onto the dorsal skin using hypodermic needles. For the negative control 
and the experimental groups, the respective uncoated and coated microneedles 
were applied onto the dorsal skin of the animals and secured with an adhesive tape 
to prevent dislodgement. After two hours, the MNs arrays were removed from the 
skin of the mice. 
For all groups, the blood samples were collected from the jugular vein at 0, 
1, 2, 3, 4 and 5 hours after the administration for the insulin aspart group while for 
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the insulin glargine group the samples were collected at time 2, 4, 6, 8, 10, 12, 14, 
16, 18, 20, 22 and 24 hours after the treatment. The samples were centrifuged at 
3000 r.p.m. for 5 min to immediately separate the plasma. Plasma glucose levels 
were measured with a glucometer (ACCU-CheckVR Active, Roche, Germany) 
whereas insulin plasma concentrations were determined using insulin ELISA kit.  
The pharmacokinetics and the pharmacodynamic parameters were 
calculated as described in session 4.1.4.3. 
 Results and Discussion. 
5.3.1 Insulin transdermal delivery in diabetic mice 
The animals were successfully induced to diabetes after 7 days of 
streptozotocin treatment showing more than 300 mg/dl of glucose levels. Figure 5.1 
shows the animals before and after the MNs treatment. 
a b 
  
Figure 5.1. Experimental mice: (a) before the MNs treatment and (b) after the MNs treatment. 
 
A 0.2 and 0.5 IU of insulin dose (1.206 and 3.017 µM, respectively) were 
selected in order to avoid hypoglycemia in the animals. The results of both fast and 
long-acting insulin treatments are individually described below. 
5.3.1.3 Fast-acting insulin treatment 
Insulin Aspart is a short-acting insulin analog with an onset of action between 
5 to15 minutes, peak action between 1 to 2 hours and a duration of action between 
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3 to 4 hours (Østerberg et al. 2003). From Figure 5.2 and Table 5.1 it is possible to 
see that except for the negative control group (uncoated MNs), all the animals 
presented a rapid decrease in the plasma glucose level within one hour. 
 
Figure 5.2. Comparative plasma glucose level vs time profiles in diabetic mice after uncoated MNs, 
subcutaneous injections and coated MNs treatments in international units (IU) (n=5). 
 
Table 5.1.Pharmacodynamic parameters for plasma glucose levels in diabetic mice after uncoated 
MNs, subcutaneous injections and coated MNs treatments (n=5). 
 
Cmin, minimum glucose level; Tmin, time point of minimum glucose level; AAC0 to 4, area above 
the plasma glucose concentration vs. time curve; RPA, relative pharmacological availability 
compared to subcutaneous injection.  
For the 0.2 IU dose treatment groups, the Cmin was reduced to about 32% of 
its initial value and no statistical difference was noted between the SC injection 
group and the MNs group (p<0.05). As expected, when the insulin dose was 
increased to 0.5 IU, a further reduction in the glucose levels was noted, reaching 
about 23% of its initial value. The rapid decrease in the glucose levels for the MNs 
treatments indicates that insulin is being absorbed very quickly; being as effective 
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Group Cmin (%) Tmin (h) AAC0-5  (%h) RPA(%)
Uncoated MNs 94.9 2 38.42 0
SC injections (0.2 IU) 33.7 1 254.08 100
SC injections (0.5 IU) 21.9 1 303.70 100
3D printed MNs (0.2 IU) 31.1 2 285.18 112
3D printed MNs (0.5 IU) 25.7 1 313.27 103
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After the first hour, the plasma glucose levels of SC injection and MNs groups 
with 0.2 IU were maintained at low levels with a slightly increase for four hours with 
no difference between them (p>0.05). After that, the plasma glucose levels start to 
rise more considerably; being more pronounced for the SC injection group. 
Interestingly though, the treatments with 0.5 IU dose shows that the SC 
injection and the MNs treatment show similar sustained low levels of glucose for 3 
hours (p>0.05). After this period, the plasma glucose level for the MNs treatment 
starts to gradually increase whereas for SC injection group, the plasma glucose level 
rises suddenly. 
The pharmacokinetic parameters were also studied, and the results are 
shown in Figure 5.3 and Table 5.2. As shown, insulin levels are quickly raised within 
one hour in all treatments.   
 
Figure 5.3. Comparative plasma insulin levels in diabetic mice after uncoated MNs, subcutaneous 
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Table 5.2. Pharmacokinetic parameters for plasma insulin levels in diabetic mice after uncoated MNs, 
subcutaneous injections and coated MNs treatments (n=5). 
 
Cmax, maximum plasma insulin concentration; Tmax, time point of maximum plasma insulin 
concentration; AUC0 to 4, area under the plasma insulin concentration vs. time curve; RBA, relative 
bioavailability compared with subcutaneous injection 
From the graph, one can see that after reached Cmax, the insulin 
concentration constantly drops to almost zero within four hours for the SC injection 
group (0.2 IU). However, when the dose is increased to 0.5 IU, the insulin 
concentration is maintained at the highest level for 3 hours before a suddenly 
decline. This event may be due to a possible depot formed into the skin allied to the 
insulin diffusion into the systemic circulation which may be responsible for the 
maintenance the high levels of insulin. 
Differently though, for both MNs treatment (0.2 and 0.5 IU), the insulin levels 
were sustained at high levels with a gradual decrease for four hours, after which a 
more pronounced reduction in the insulin concentration can be seen. Moreover, no 
difference could be seen between for the 0.5 IU dose of SC injections and MNs for 
3 hours (p>0.05). 
The glucose responses are also consistent with the insulin doses. Similar 
sustainable insulin levels and hypoglycemic responses were also reported by others 
using biodegradable MNs loaded with insulin (Zhang et al. 2018; Yu, Jiang, Zhang, 
et al. 2017; Liu et al. 2012). The observed maintenance of the pharmacological 
activity can be attributed to both the MNs formulation and to the passive diffusion of 
the insulin. 
5.3.1.4 Long-acting insulin treatment 
Insulin glargine is a long-acting insulin analog administered as a solution 
which precipitates into the subcutaneous tissue and it is slowly released being 
absorbed at a constant rate. It has an onset of action between 2 to 4 hours and a 
Group Cmáx (µIU.mL
-1
) Tmáx (h) AUC0-5  (µIU.mL
-1
.h) RBA(%)
Uncoated MNs 0 0 0.00 0
SC injections (0.2 IU) 49.2 1 125.07 100
SC injections (0.5 IU) 71.5 1 223.34 100
3D printed MNs (0.2 IU) 60.1 2 194.41 155
3D printed MNs (0.5 IU) 81.6 1 223.34 115
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duration of action between 20 to 24 hours (Barnett 2006). Figure 5.4 and Table 5.3 
shows the pharmacodynamic of insulin upon the treatments. 
 
Figure 5.4. Comparative plasma glucose level vs time profiles in diabetic mice after uncoated MNs, 
subcutaneous injections and coated MNs treatments in international units (IU) (n=5). 
 
Table 5.3. Pharmacodynamic parameters for plasma glucose levels in diabetic mice after uncoated 
MNs, subcutaneous injections and coated MNs treatments (n=5). 
 
Cmin, minimum glucose level; Tmin, time point of minimum glucose level; AAC0 to 4, area above 
the plasma glucose concentration vs. time curve; RPA, relative pharmacological availability 
compared to subcutaneous injection.  
From the graph, it is possible to see that both MNs and SC injection groups 
presented similar behaviour up to 18 hours. A rapid decrease in the glucose levels 
followed by a sustained minimum glucose level up to 18hs can be seen for all insulin 
treatments. No difference could be seen between the SC and MNs for the 0.2 IU 








0 2 4 6 8 10 12 14 16 18 20 22 24
Uncoated MNs SC injections (0.2 IU) SC injections (0.5 IU)




















Group Cmin (%) Tmin (h) AAC0-24  (%h) RPA(%)
Uncoated MNs 97.6 20 3.44 0
SC injections (0.2 IU) 40.8 14 1252.70 100
SC injections (0.5 IU) 32.8 18 1425.31 100
3D printed MNs (0.2 IU) 39.9 20 1320.98 105
3D printed MNs (0.5 IU) 29.2 10 1579.93 111
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(0.2 and 0.5 IU) showed a faster increase in the glucose levels whereas for the MNs 
group, they tended to increase more slowly. 
Figure 5.5 and Table 5.4 shows the pharmacokinetic parameters of the 
plasma insulin levels of all treatment groups. 
 
Figure 5.5. Comparative plasma insulin levels in diabetic mice after uncoated MNs, subcutaneous 
injections and coated MNs treatments in international units (n=5). 
 
Table 5.4. Pharmacokinetic parameters for plasma insulin levels in diabetic mice after uncoated MNs, 
subcutaneous injections and coated MNs treatments (n=5). 
 
Cmax, maximum plasma insulin concentration; Tmax, time point of maximum plasma insulin 
concentration; AUC0 to 4, area under the plasma insulin concentration vs. time curve; RBA, relative 
bioavailability compared with subcutaneous injection 
Except for the treatment with the MNs loaded with 0.5 IU, all insulin 
treatments showed an initial peak of insulin plasma concentration at 2 hours which 
is decreased in about 50% in the next 2 hours. At this point, insulin levels are 
sustained for 4 hours. Interestingly though, the levels of insulin in the plasma start 
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) Tmáx (h) AUC0-24  (µIU.mL
-1
.h) RBA(%)
Uncoated MNs 0 0 0.00 0
SC injections (0.2 IU) 14.0 12 271.03 100
SC injections (0.5 IU) 15.9 12 300.85 100
3D printed MNs (0.2 IU) 12.9 12 247.88 91
3D printed MNs (0.5 IU) 26.8 12 419.71 140
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24 hours experiment. This behaviour might be due to changes in the equilibrium of 
the dissolution of the precipitated insulin. 
Even though the microneedles containing the 0.5 IU of insulin presented a 
significant superior release behaviour than the SC injection with the same dose 
(p<0.05) no statistical difference was noted on the level of glucose response for 18 
hours. 
  Conclusions 
The animal studies revealed that insulin retained its pharmacological activity 
on the microneedles. Overall, the MNs provided a fast and efficient delivery of insulin 
for all treatments, producing a significant hypoglycemic response with a sustained 
effect. Moreover, the MNs treatment also presented higher relative bioavailability 
and pharmacological availability than the subcutaneous injections.  
Moreover, once insulin therapy aims to mimic the normal physiological insulin 
response, the sustained release of insulin glargine is desired for a basal insulin 
therapy, however it is not suitable for a bolus therapy (insulin aspart). In this case, 
insulin levels should return to the basal levels between 2-3 hours. 
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CONCLUSIONS AND FUTURE WORK 
Diabetes is considered a global epidemic disease that affects more than 425 
million people worldwide. In many cases, the administration of exogenous insulin is 
necessary for the treatment, however, the patient compliancy can be very low due 
to the anxiety and fear of needles. In this sense, transdermal microneedle arrays 
can provide a safe and painless alternative for insulin treatment. 
In this study we developed coated microneedles for rapid transdermal 
delivery of insulin using metallic and polymeric microneedles. All different designs 
of polymeric microneedles were successfully fabricated by a biocompatible resin 
class I using stereolithography. Furthermore, the 3D printed microneedles offered a 
larger area for drug deposition and superior penetration capacity compared to the 
metallic microneedle’s ones. Our results also showed that the inkjet printing 
technique was successfully used for depositing uniform and accurate coatings on 
the surface of the microneedles, overcoming the drawbacks imposed by other 
coating methods. 
Among all the carriers studied for the coating formulations, the sugars, 
specially xylitol, demonstrated the best insulin stability performance. Overall, the 
release studies showed rapid release rates within 30 min. The animal studies 
revealed that the insulin treatments with the 3D printed microneedles provided fast 
and efficient delivery of insulin producing a significant hypoglycemic response with 
a sustained effect.  
Further investigations about the mechanical strength of the microneedles are 
needed to provide a better understanding of the developed 3D printed MNs. The 
study of the long-term stability of the coated formulations, the transepidermal water 
loss and human models would also be interesting. 
